Trading Analysis Report: COHR¶

Analysis date: 2026-10-21
Rating: Hold
Generated: 2026-10-21 11:57:05
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 237.37 Price As Of: 2026-10-21

COHR (Coherent Corp., NYSE): technical report as of 2026-10-21¶

1. Summary¶

COHR is in a sharp, high-volatility downtrend inside a larger uptrend that has broken down. The close of 237.37 is 29.8% below the 338.36 close on 2026-10-06, only 11 sessions earlier. It is 44.4% below the cycle-high close of 426.89 on 2026-06-02. The signals conflict:

Bearish: The weekly SuperTrend, the daily SuperTrend, the moving-average structure, MACD and ADX all point down.
Bounce case: The daily TD Sequential has completed a buy-setup 9, price sits near a repeatedly tested low zone, and the MACD histogram has just ticked up.
Net read: The primary trend is down, with a tactical bounce set-up inside it. No tool output confirms a reversal.

The monthly SuperTrend stop at 228.68 is the key level, about $8.69 below the close.

2. Data integrity notes¶

Provisional bar: The 2026-10-21 volume is 3,045,065, well below the 6–10M of recent sessions. The bar may be incomplete or provisional, so treat the close, OBV and MFI-type readings for today as subject to change.
SuperTrend percentages: The tool's distance-to-stop percentages differ slightly from my arithmetic using the verified close.

Tier	Tool figure	My arithmetic
Monthly	+3.69%	about +3.8%
Daily	−18.84%	about −18.75%

The gaps are about 0.1 percentage point and don't change the conclusions. The snapshot doesn't independently verify the SuperTrend stop levels. - Snapshot cross-check: RSI (35.45), MACD histogram (−8.96) and ATR (20.95) from the indicator tool all match the verified snapshot. - ADX direction: I did not pull +DI/−DI, so ADX direction is inferred from price and SuperTrend, not measured directly.

3. Price action and structure¶

Longer arc (from the OHLCV data): - The stock rose from a 120.79 close on 2025-10-21 to a 426.89 close on 2026-06-02. The intraday high was 440.00 on 2026-06-03. - The 2026-06-22 high of 439.68 nearly matched that peak, so there was a double-top-like area near 440. - Since then the rally highs have been lower:

Date	Intraday high
2026-06-03	440.00
2026-06-22	439.68
2026-08-07	391.37
2026-10-05	341.76

Recent leg: - The stock closed at 337.04 on 2026-10-02, then fell to 232.90 by 2026-10-16. - The last three closes are 232.90, 232.02 and 231.80, then 237.37 today. That is a tight stall after a roughly 31% drop. Volume faded over the same stretch, from 9.95M on 2026-10-15 to 7.96M, 6.59M and 6.15M. Today's volume is incomplete. - Today opened at 240.44, above the prior close of 231.80, and closed up about 2.4%.

Low zone near 215–222. Three dated lows cluster here:

Date	Intraday low	Close	What followed
2026-03-30	215.55	219.65	Closed 238.21 the next day and reached 347.51 by 2026-04-20
2026-07-29	220.68	222.05	Closed 249.06 the next day and reached 379.13 by 2026-08-07
2026-10-20	217.83	231.80	Closed 237.37 on 2026-10-21

The Bollinger lower band at 215.09 sits inside this zone. The previous two tests were followed by large rebounds. That is a fact about those two episodes, not a reliable pattern.

Unfilled gap. On 2026-10-14 the low was 261.90. On 2026-10-15 the high was 252.28. This leaves an overhead gap of roughly 252–262 that a relief rally could target. The 10-EMA at 259.04 sits inside it.

Below 215. The last visible structure in the data is the Dec 2025–Feb 2026 range, with lows between about 170 and 210. Examples are 170.12 on 2025-12-17, 167.50 on 2026-01-09 and 175.24 on 2026-02-05. There is little traded structure between about 215 and 210.

4. Indicators¶

Trend¶

Moving averages (snapshot):

Average	Level	Close vs. level
10-EMA	259.04	about 8.4% below
50-SMA	293.22	about 19% below
200-SMA	295.19	about 19.6% below

The close is below all three.
The 50-SMA is below the 200-SMA by about 1.97, a bearish ordering.
The 50-SMA, 200-SMA, Bollinger midline (287.63) and daily SuperTrend (292.15) all sit between about 288 and 295. That is a dense resistance cluster about 21–24% above the current price. Any recovery that reaches it will meet confluence.

SuperTrend (14, 3× ATR), where the higher tier wins:

Tier	Direction	Stop	Note
Weekly (primary)	DOWN	395.74	Close is about 40% below the stop
Monthly (regime)	UP	228.68	Close is about $8.69 above the stop
Daily (timing)	DOWN	292.15	Close is about 19% below the stop

The weekly trend is down, so the primary trend is bearish.
The monthly regime is still up, but only barely. The 2026-10-20 close of 231.80 held 3.12 above the stop, even though the intraday low of 217.83 went well below it.
A close through the line flips the trend. Because this is a monthly bar, the relevant close is the October month-end. My calendar read is about seven sessions remain, which isn't from the tool. Treat that timing as an inference.
A month-end close below 228.68 would put all three SuperTrend tiers in a downtrend.

ADX: 35.56. - It was 8.19 on 2026-10-09 and has been above 25 since 2026-10-16. A tradable trend is now established, and it is the downward move. - ADX is a lagging, smoothed measure. It tends to keep rising after a sharp move even as the move stalls, so the high reading alone doesn't say the fall will continue.

Momentum¶

RSI: 35.45. - It has held between 33.2 and 35.5 over the last four sessions and has not reached the 30 oversold threshold. - The fall to 232.90, 232.02 and 231.80 came with a flat RSI (33.37, 33.21, 33.17), so there is no bullish divergence yet. - RSI was last above 60 on 2026-10-02 and 2026-10-06, around the local top.

MACD (snapshot): - The MACD line is −16.94, below the signal at −7.98 and below zero. - The histogram turned negative on 2026-10-12 (−0.73) and reached −9.85 on 2026-10-20. It improved to −8.96 today, the first narrowing in the series. - That is an early sign of downside momentum slowing. A bullish crossover would need the histogram to cross back above zero, which is a long way off.

Volatility¶

ATR: 20.95, about 8.8% of the price. Volatility is very high. Daily ranges of 5–10% have been common in the recent data.
Bollinger Bands: The lower band is 215.09, the midline 287.63 and the upper band 360.17. The close sits at about 15% of the band width, so it is in the lower part of the band but not outside it. The bands are wide because of the recent swings.
ATR-based reference levels (arithmetic only, not support levels):
1× ATR below the close is about 216.4. This is near the 215–222 low zone.
2× ATR below is about 195.5.

Volume¶

OBV: 270.4M, against 312.0M on 2026-10-02. It made a window low of 267.4M on 2026-10-20, the same day as the price low close in the window.
OBV confirms the selloff. There is no bullish divergence, but selling has not been extreme in the last two sessions.
Today's OBV uptick comes from a partial-volume bar, so it carries little weight.

Exhaustion and stretch¶

TD Sequential:

Tier	Count	Meaning
Daily	+9	Buy setup complete (reversal watch)
Weekly	+2	Early
Monthly	+3	Early

The completed daily 9 flags possible exhaustion of the recent decline.
The weekly and monthly setups are only at the start, so the higher tiers show no exhaustion. Under the tool's weighting, the daily signal is a tactical watch, not a trend-change signal.
A completed 9 can be followed by a bounce, a pause or a continued decline.

Z-score (20-period):

Tier	Reading
Weekly	−1.59
Daily	−1.39
Monthly	+0.40

Nothing reaches the ±2 stretch threshold, so the mean-reversion trigger is not met even after a roughly 30% fall. The 20-period standard deviation has widened with the volatility.
The weekly z-score is closest to a stretch, but not yet there.

5. Scenarios and key levels¶

Level	Value	Basis
Resistance 1	252–262	Unfilled gap from 2026-10-14/15, plus the 10-EMA at 259.04
Resistance 2	287.6–295.2	Bollinger midline, daily SuperTrend, 50-SMA and 200-SMA
Resistance 3	395.74	Weekly SuperTrend stop (trend flip level)
Pivot / regime line	228.68	Monthly SuperTrend stop
Support zone	215–222	Lows on 2026-03-30, 2026-07-29 and 2026-10-20, plus the lower band at 215.09
Below support	about 170–210	Dec 2025–Feb 2026 trading range

Bounce scenario. - Triggers: the daily TD-9, the MACD histogram turning up, and price holding above 228.68. - Realistic first targets are the 10-EMA and the gap near 252–262. That is about 9–10% above the current price. - The 287–295 cluster is about 21–24% above and would be the first area where the larger trend structure resists. - Confirmation would be volume expanding on up days. Today's data can't show that yet.

Continuation scenario. - Triggers: a month-end close below 228.68, which flips the monthly SuperTrend, and then a break of the 215–222 zone. - The low zone has held three times, but each break of a level that has held for months can accelerate. Daily moves of 5–10% are common in this data.

Risk sizing. - The 215–222 zone is about 8–9% below the close. - The first overhead target is about 9% above. The 287–295 cluster is about 23% above. - With an ATR of about 8.8% of price, stops inside one ATR are likely to be hit by normal noise.

6. Limits of this analysis¶

Earnings: Large gaps appear in the data, for example the 2025-11-06 open of 153.70 against a prior close of 134.63. I can't confirm the next earnings date from these tools, so check the calendar.
Not retrieved: +DI/−DI, MFI and stochastic indicators.
Today's bar: The close and volume are likely to change if the session isn't final.

Summary table¶

Item	Reading	Interpretation
Latest close (2026-10-21)	237.37	Up about 2.4% from 231.80 on 2026-10-20
Drawdown	−29.8% from 338.36 (2026-10-06); −44.4% from 426.89 (2026-06-02)	Sharp, deep correction
10-EMA / 50-SMA / 200-SMA	259.04 / 293.22 / 295.19	Price below all; 50 below 200
SuperTrend weekly	DOWN, stop 395.74	Primary trend bearish
SuperTrend monthly	UP, stop 228.68 (about $8.69 below)	Regime at risk; month-end close below 228.68 flips it
SuperTrend daily	DOWN, stop 292.15	Short-term bearish
ADX	35.56 (from 8.19 on 2026-10-09)	Strong, established trend (downward by price)
RSI	35.45	Weak, not oversold; no divergence
MACD / signal / histogram	−16.94 / −7.98 / −8.96	Bearish; histogram narrowing for the first time
ATR	20.95 (about 8.8% of price)	Very high volatility
Bollinger (lower / mid / upper)	215.09 / 287.63 / 360.17	Lower half of band; lower band inside the 215–222 low zone
OBV	270.4M (window low 267.4M on 2026-10-20)	Confirms the selloff; no divergence
TD-9 (daily / weekly / monthly)	+9 / +2 / +3	Daily exhaustion watch; higher tiers early
Z-score (weekly / monthly / daily)	−1.59 / +0.40 / −1.39	Below average but not stretched (±2)
Key support	215–222	Three dated lows, plus the lower band
Key resistance	252–262, then 287.6–295.2	Gap and 10-EMA, then confluence cluster
Data flag	2026-10-21 volume of 3.05M	Possibly incomplete bar
Technical lean	Bearish primary trend with a tactical bounce set-up	No confirmed reversal; the trade decision is for the next agent

Sentiment Analyst¶

Overall Sentiment: Mixed (Score: 5.0/10) Confidence: Medium

Scope and data quality. Window: 2026-10-14 to 2026-10-21, ticker COHR (Coherent Corp., NYQ). News returned 20 headlines, but several are tangential (Apple titanium, BayAreaCMO awards, a photonic IC market report). StockTwits returned 30 messages, of which 9 are labeled Bullish, 0 Bearish and 21 unlabeled. Reddit was disabled by config, so there is no Reddit read. With one of three sources missing and a thin set of labeled retail posts, confidence is medium. No price or volume tool output was provided. Price figures below come from user posts and are unverified.

1. Source-by-source breakdown

News (institutional framing): cautious on price action and analyst targets, constructive on the demand backdrop. - Negative: Susquehanna cut its COHR price target to $350 from $425 (MT Newswires, Stocktwits). The same note raised AMD and QCOM targets and cut INTC and COHR, with an overall 'modest upside' view for chip earnings. $350 is still well above the roughly $230 level cited by retail users, so this is a target reset, not a thesis break. The rationale for the cut is not in the headlines provided. - Negative: Investor's Business Daily ran 'Chip Stocks Tumble On AI Investment Worries' and 'Chip Stocks Continue Downward Streak, Pricing In A Crash', so sector tape pressure was heavy in the window. A 'Top Midday Decliners' item appears, but its body is not included, so I cannot confirm COHR was on it. - Negative: peer AAOI was described as down about 50% over six months, and a Motley Fool piece said it 'plummeted this week'. That points to stress across the optical-component group. - Positive: Stocktwits/TrendForce says an AI fiber shortage is driving prices higher, with a supply crunch seen through 2028. COHR is named as 'in focus' alongside GLW and VZ. - Positive: 24/7 Wall St. reported 'Optics Stocks Rally Ahead of Earnings' (AAOI +5%, LITE +4%, COHR +2%). It also reported that Coherent edged higher on 3M's expanded Amazon data center deal. Barron's ran 'The AI Trade Is Working Again'. - Neutral: Insider Monkey ran a valuation piece ('Fairly Valued?') and a CPO piece ('could benefit from AI networking even if CPO adoption takes time'). The CPO piece frames co-packaged optics as a slower-than-hoped adoption path but not a threat. Barchart ran an earnings preview, which implies the next quarterly report is approaching, but the date is not given in the evidence. Simply Wall St. noted the AI capacity buildout and TSX CDR listing.

StockTwits (retail, 30 messages): leans bullish among labeled posts, but conviction is thin and heavily concentrated. - Labeled split is 9 Bullish (30%) / 0 Bearish (0%) / 21 unlabeled. The 0% bearish share is not a clean all-clear. Several unlabeled posts are cautious or frustrated, and the unlabeled majority limits how much the ratio says. - The bullish count is concentrated. @Sieppo accounts for 3 of the 9 bullish tags (dip-buying, 'bounced at the 220ish support', rebutting 'bears' with data center capex arguments). Several posts repeat the same Musk bandwidth-demand quote, so apparent breadth is overstated. - Specific bullish actions: @Mj2_stocks bought Feb 2027 $300 calls. @cmoney0417 is 'full porting' on the claim that Nvidia bought $2B of Coherent at a price about 20 points higher (user claim, not verified in the evidence). @Nicksstockz says 'run it back to 300… or 400'. @bigsnipe is 'reopening here'. @SuperGreenToday posted a Nov 13 $230 call idea with spot at $231.82 on Oct 20. - Technical framing from retail: support at $220-225 ('double bottom bounce off the $225 support', 'at 220 level you'd have to try here again'), with $250 as a gap-fill target. @JFDI wrote 'on the floor'. - Cautious or negative: @kevie6537 hopes COHR closes under $230 Friday and expects a pullback until a peace deal is signed. @discocelsior1 is 'not buying into this rally' and holding cash. @mmr786 says the stock 'rarely participates on the upside and always has oversized downside moves' and regrets not buying CRDO. @Sarge986 shared a chart titled 'COHR Rose Some 450% Over a Year, Then Tanked'. - Quantitative context: @nth_effect says COHR is down 20.1% over five days against Arista's 11.4% decline, an 8.7-point gap. They read it as the market sorting component suppliers with uncertain margin profiles from other AI-networking names. This is a user-supplied figure, not verified.

Reddit: disabled by configuration. There is no read from r/wallstreetbets, r/stocks or r/investing, and no inference should be drawn about them.

2. Cross-source divergences and alignments - Divergence: retail is leaning into the dip (labeled posts 100% bullish, call buying, 'back to 300-400' calls). The institutional/news side is more cautious, with a target cut, sector-wide chip selloff headlines, and COHR-specific relative weakness. Retail is effectively betting on mean reversion against a falling tape, so there is risk of catching a falling knife if the $220-225 support fails. - Divergence: news carries a clear fundamental positive (AI fiber/optics supply shortage through 2028, data center buildout, Amazon/3M deal) that coexists with negative price action. Sentiment is therefore split between demand fundamentals and valuation or positioning. - Alignment: both sources recognise that COHR has sold off hard. News shows the target cut and sector decline, and StockTwits shows the 20% five-day drop and the 'tanked after 450%' framing. Both also lean on AI data-center capex as the key driver in either direction. - Alignment on peers: COHR is traded as a basket with LITE, AAOI, GLW, POET and MRVL on both sources, so sector beta matters more than company-specific news.

3. Dominant narrative themes 1. AI capex durability. This is the central debate: 'AI investment worries' (IBD) against retail rebuttals that data center spending is accelerating, with posts citing Musk's bandwidth quote and a reported $35-40B Q4 capex figure. Those figures are user-cited and unverified. 2. Optics/fiber supply crunch. TrendForce is cited as seeing tightness through 2028. 3. Post-run-up drawdown and volatility. Retail frustration centers on outsized downside moves after a large multi-month rally. 4. Analyst target resets. Susquehanna lowered its COHR target while raising others, and a retail user said they do not agree with the 'price downgrades'. 5. Macro/geopolitical overlay. Several posts tie short-term direction to peace-deal headlines. 6. CPO/photonics technology narrative. It is supportive (Insider Monkey, Shkreli photonic chip commentary) but with adoption timing uncertain.

4. Catalysts and risks surfaced - Catalysts: the upcoming quarterly earnings report (preview published, date not provided in the evidence); continued hyperscaler capex announcements; optics supply tightness and pricing; sector rebound ('AI trade is working again'); defense of $220-225 support and a retest of the $250 gap, per retail technical talk. - Risks: further chip-sector derisking on AI-spend worries; more analyst target cuts; a break below $220-225 support; margin uncertainty for component suppliers, which retail commentary says is driving the sort between AI-networking names; CPO adoption delays; geopolitical headline swings; high-volatility, high-beta behavior that frustrates holders. Heavy call-option chatter (Feb 2027 $300, Nov $230) points to leveraged retail positioning that can amplify moves in both directions.

5. Summary table

Signal	Direction	Source	Evidence
Susquehanna target cut to $350 from $425	Bearish	News (MT Newswires, Stocktwits)	Cut alongside INTC while AMD and QCOM were raised; $350 is still far above the cited ~$230 spot
Chip stock selloff on AI investment worries	Bearish	News (IBD)	'Tumble' and 'Pricing In A Crash' headlines
COHR -20.1% over 5 days vs Arista -11.4%	Bearish (relative)	StockTwits (@nth_effect)	User-cited, unverified; suggests supplier-specific pressure
AI fiber shortage, supply crunch through 2028	Bullish	News (Stocktwits/TrendForce)	COHR named alongside GLW and VZ
Optics rally, Amazon/3M data center deal	Mildly bullish	News (24/7 Wall St.)	COHR +2% in the optics rally; edged higher on the 3M news
Labeled retail ratio 9 Bull / 0 Bear / 21 unlabeled	Bullish, low depth	StockTwits	30 messages; @Sieppo accounts for 3 of 9 bullish tags; repeated duplicate quotes
Dip-buying and call buying (Feb 2027 $300 calls)	Bullish	StockTwits	@Mj2_stocks, @cmoney0417, @bigsnipe reopening
Support at $220-225, target $250 gap	Neutral to bullish (technical)	StockTwits	Double-bottom bounce talk; spot ~$231.82 on Oct 20
Frustration with volatility and caution	Mildly bearish	StockTwits	@mmr786, @discocelsior1, @kevie6537 expect a pullback
CPO adoption timing	Neutral	News (Insider Monkey)	Benefits from AI networking even if CPO adoption takes time
Upcoming earnings	Event risk, direction unknown	News (Barchart)	Preview published; date not provided in evidence
Reddit	No data	Reddit	Disabled by config

Bottom line: sentiment on COHR is Mixed. Retail is dip-buying with call buying and no labeled bearish posts, but breadth is narrow and many unlabeled posts show nerves. Institutional-style news is split between a target cut and sector selloff on one side and a strong optics-supply and AI-capex backdrop on the other. The evidence does not support a clean directional call. Treat this as sentiment context to weigh against fundamentals and technicals, since past sentiment is not predictive.

News Analyst¶

COHR (Coherent Corp.): News and Macro Report, 14–21 Oct 2026¶

1. Data coverage and gaps¶

FRED macro data failed. Every get_macro_indicators call returned DATA_UNAVAILABLE. That covers fed funds, 10Y, yield curve, CPI, unemployment, VIX and the raw series IDs. I have no figures for those series and have not estimated any. Prediction markets stand in for the Fed picture below, but they are a weaker substitute.
News came back as headlines only. I had no article text, no timestamps and no price data. I can't give COHR's current price, its move this week, or its upside to any price target.
No earnings date was returned. A Barchart preview, "What to Expect From Coherent's Next Quarterly Earnings Report," exists, but its content wasn't retrieved. Check the date separately. Coherent has historically reported its fiscal Q1 in early-to-mid November, which is my own recollection and not from the tools.

2. COHR company news¶

Analyst action (the clearest negative datapoint) - Susquehanna cut its COHR price target to $350 from $425 (MT Newswires). That is about a 18% cut. A Stocktwits headline groups COHR with INTC as facing target cuts, while AMD and QCOM got raises. Susquehanna reportedly sees "modest upside" for chip earnings overall. - A target of $350 still implies a high share price. I can't tell whether it is above or below the current price.

Demand and fundamentals (positive) - Fiber shortage: TrendForce sees an AI-driven fiber supply crunch through 2028, pushing prices higher (GLW, VZ and COHR named). This supports pricing power and demand visibility across optical networking. - Data-center capex: 3M jumped about 6% on an expanded Amazon data center deal and an earnings beat. Coherent "edged higher" and Corning was flat on the same day. That suggests sympathy with the theme rather than a COHR-specific catalyst. - Optics sector rally into earnings: AAOI rose about 5%, LITE about 4% and COHR about 2% (24/7 Wall St.). Peers are trading into their own prints. - Capacity and listing: Simply Wall St. highlights Coherent's AI capacity buildout and its TSX CDR listing. That could widen the investor base, but the headline gave no detail.

Risks and debates - CPO adoption timing: Insider Monkey says COHR can benefit from AI networking "even if CPO (co-packaged optics) adoption takes time." That implies the market is debating whether CPO could disrupt pluggable transceivers, which are core to COHR and LITE. - Peer weakness: AAOI is down about 50% over six months, and one headline says it "plummeted this week." This shows how fragile sentiment is in small-cap optics. - Chip-sector selloff headlines: IBD ran "Chip Stocks Continue Downward Streak, 'Pricing In A Crash'" and "Chip Stocks Tumble On AI Investment Worries." Barron's ran "The AI Trade Is Working Again." These are undated, so I can't confirm the order. Together they suggest sentiment swung hard in both directions during the window. - Valuation debate: Insider Monkey asks "Is Coherent Fairly Valued?" I have no content on its conclusion. - Noise: Shkreli's photonic-chip commentary and the PIC market report (19.3% CAGR through 2030) are low-signal.

3. Macro and market backdrop¶

Fed expectations (Polymarket) | Market | Probability | Volume / note | |---|---|---| | Oct 2026 FOMC: no change | 86% | $15.3M, up 20pp on the week, resolves Oct 29 | | Oct 2026 FOMC: +25bp hike | 12% | $12.0M, down 20.5pp on the week | | Oct 2026 FOMC: any cut | ~0% | Deep volume | | No Fed cuts in all of 2026 | 97% | $9.0M | | "Another Fed rate hike in 2026?" | 80% | $0.9M, resolves Dec 10 |

The market is pricing no cuts and a real chance of further tightening. A hike was priced at roughly a third a week ago and has faded for October.
The "another hike" and "2 hikes in 2026" contracts (70%) imply a hike already happened this year and another by December is likely. This is my inference from the contract titles. Those contracts are thin (under $1M), and I couldn't check it against FRED.
The takeaway is a "higher for longer, possibly higher" rate regime. That is a headwind for long-duration, high-multiple growth names like COHR.

Growth and AI-cycle risk - US recession by end-2026: 8% ($2.3M volume). Recession fear is low. - AI bubble bursts in 2026: 9% (up 3.1pp on the week, $2.5M volume). By June 2027: 20% (very thin). Tail risk is small but rising, which fits the chip-selloff headlines. - NVDA Q3 (reports around Nov 18): the Data Center revenue >$100B contract is at 81% and >$110B at 20%. These markets are very thin (under $3K volume), so treat them as anecdotal. NVDA's print is a major sector catalyst after COHR's.

Other - Gold edged up and oil slipped (WSJ). - Equities rose pre-bell ahead of Meta and Tesla earnings. - IBM, Palantir and Meta prints are all in focus. Hyperscaler capex commentary from Meta and others is the key read-through for optical demand. - Prediction markets had nothing on semiconductor tariffs or China trade, so I can't quantify that risk.

4. Takeaways for traders (evidence only, not a recommendation)¶

Fundamental thesis intact, with a rich-valuation caveat. The AI fiber shortage through 2028, hyperscaler data center deals and sector rallies support demand. The Susquehanna cut shows analysts trimming price targets, possibly on valuation or multiple compression.
Sentiment is volatile. Headlines swing between "pricing in a crash" and "AI trade is working again." AAOI's collapse shows how violent moves in optics can be. Expect high beta around catalysts.
Catalysts to watch:
COHR fiscal Q1 earnings (date unconfirmed).
Oct 28–29 FOMC. A hawkish surprise or dissents would hurt high-multiple tech.
Hyperscaler capex commentary from Meta, Microsoft, Alphabet and Amazon earnings.
LITE and other optics earnings as read-throughs.
NVDA earnings around Nov 18.
Key risk factors:
Rate-hike risk.
AI-capex digestion fears.
CPO displacing pluggables.
Any China or export-control or tariff shock, which this data can't size.
Open items for the next analyst. Get COHR's price and technicals, the confirmed earnings date, and Susquehanna's reasoning. Also get the actual Fed funds, 10Y and CPI readings once FRED is back.

5. Summary table¶

Category	Key point	Source / evidence	Implication for COHR
Analyst action	Susquehanna PT cut to $350 from $425	MT Newswires, Stocktwits	Mildly negative. Analysts are trimming, but a $350 target is still high
Demand	AI fiber shortage through 2028	TrendForce via Stocktwits	Positive for pricing and volume
Data center capex	3M–Amazon deal. COHR edged up, GLW flat	24/7 Wall St.	Supportive theme, sympathy move only
Sector flow	Optics rally pre-earnings (AAOI +5%, LITE +4%, COHR +2%)	24/7 Wall St.	Positive near-term momentum
Sector risk	Chip selloff headlines ("pricing in a crash"). AAOI down about 50% in six months	IBD, Motley Fool	Sentiment fragile, high beta
Tech debate	CPO adoption timing	Insider Monkey	Long-term risk to pluggables, near-term benefit remains
Corporate	TSX CDR listing, AI capacity buildout	Simply Wall St.	Broader investor base, details unknown
Fed (Oct 28–29)	86% hold, 12% hike, ~0% cut	Polymarket ($15M volume)	Hawkish skew is a headwind for growth multiples
Fed (2026)	97% no cuts. 80% "another hike" by Dec 10 (thin market)	Polymarket	Higher-for-longer, possibly tighter
Recession / AI bubble	Recession 8%. AI bubble burst in 2026 at 9% (up 3.1pp)	Polymarket	Low but rising tail risk
Upcoming catalysts	COHR earnings (date TBD), FOMC Oct 28–29, hyperscaler earnings, NVDA about Nov 18	News and Polymarket	Event-driven volatility ahead
Data gaps	FRED macro, price data and earnings date unavailable	Tool errors	No CPI, yield or VIX readings. Verify before trading

Fundamentals Analyst¶

COHR (Coherent Corp.) – Fundamental Report¶

As of 2026-10-21. Technology / Scientific & Technical Instruments, NYSE. Fiscal year ends June 30.

0. Scope and data notes¶

Nothing in the tool output is dated within the past week. The newest financials are the FY2026 annual figures (year ended 2026-06-30). The newest insider filing is dated 2026-09-11. This report covers the latest complete fundamental picture.
Implied price: the fundamentals feed has no spot price. P/E × EPS (57.61 × 4.12), forward P/E × forward EPS, and P/B × book value (4.26 × 55.7) all give about $237. Treat that as a derived figure.
Derived June quarter: the quarterly tool stops at 2026-03-31. I backed out Q4 FY26 as FY26 minus the first three quarters. Those figures are my arithmetic, not reported numbers.
Missing detail: the tools don't break out inventory, receivables, debt, share count or segments. Some points below are inferences and are labeled that way.

1. Snapshot and valuation¶

Metric	Value	Comment
Market cap	$46.7B
Price (implied)	~$237	About 46% below the 52-week high of $440, about 110% above the low of $112.96
50-day / 200-day average	$295.0 / $294.9	Price is about 20% below both
Beta	2.11	Very high volatility
P/E (TTM, GAAP)	57.6x	EPS $4.12
Forward P/E	17.1x	Forward EPS $13.92, about 3.4x TTM
PEG	0.92
P/B	4.26	Book value per share $55.7
P/S (TTM)	~6.6x
EV/EBITDA (approx.)	~34x	EV about $49B. Debt is backed out of D/E at about $3.45B, less $1.16B cash. EBITDA is $1.42B.
Dividend	0%

Forward EPS gap: forward EPS is probably on an adjusted (non-GAAP) basis, and TTM EPS is GAAP. That likely overstates how fast earnings are expected to grow. Check the basis before relying on the 17x.
Priced for execution: the stock trades at a rich TTM multiple with a high beta. It sits well below its recent trend averages.

2. Income statement¶

Annual trend ($M) | FY (June) | Revenue | YoY | Gross margin | Net income | Diluted EPS | |---|---|---|---|---|---| | FY23 | 5,160 | | 31.4% | -259 | -2.93 | | FY24 | 4,708 | -8.8% | 30.9% | -159 | -1.84 | | FY25 | 5,810 | +23.4% | 35.2% | 30 | -0.52 | | FY26 | 7,118 | +22.5% | 37.5% | 787 | 4.12 |

FY26 by quarter ($M) | Quarter | Revenue | YoY | QoQ | Gross margin | Net income | EPS | |---|---|---|---|---|---|---| | Q1 (Sep-25) | 1,581 | +17.3% | +3.4% | 36.6% | 226 | 1.19 | | Q2 (Dec-25) | 1,686 | +17.5% | +6.6% | 36.9% | 147 | 0.76 | | Q3 (Mar-26) | 1,806 | +20.6% | +7.1% | 37.6% | 191 | 0.97 | | Q4 (Jun-26), derived | ~2,045 | ~+34% | ~+13% | ~38.5% | ~223 | ~1.20 |

Growth is accelerating. Year-over-year growth went from 17% to 34% across the year. Sequential growth went from 3% to 13%.
Margins are expanding. Gross margin rose from about 29% in late 2023 to about 38.5% in the derived Q4.
Profitability swung from losses to profit. Net income was -$159M in FY24 and $787M in FY26. TTM operating margin is 11.8%, EBITDA margin about 20%, and net margin about 11%.
Low returns on a larger equity base. ROE is 8.0% and ROA is 3.4%, because equity roughly doubled (see §3).
Minor vendor mismatches: fundamentals net income is $770M against $787M in the annual filing. The stated profit margin of 11.3% implies about $805M.

3. Balance sheet (FY26, 2026-06-30)¶

$M	FY25	FY26	Change
Total assets	14,911	18,300	+23%
Current assets	3,927	6,925	+76%
Cash	909	1,162	+28%
Current liabilities	1,795	2,854	+59%
Total liabilities	6,430	7,062	+10%
Stockholders' equity	5,645	10,903	+93%

Liquidity is solid. The current ratio is 2.43. Debt/equity is 0.32x, with total debt of roughly $3.45B and net debt of roughly $2.3B (about 1.6x EBITDA).
Equity roughly doubled (inference from the quarterly data):
Preferred conversion: total assets less liabilities less equity was about $2.8B through Sep-25 and about $0.35B from Dec-25 on. That points to roughly $2.5B of mezzanine convertible preferred converting to common in the Dec-25 quarter. That conversion is consistent with Bain Capital's Nov-2025 share sale (see §5).
Equity raise: Q3 FY26 financing inflow was about +$1.85B, and equity rose about $2.1B that quarter. That looks like a large equity raise.
Dilution: the share base is larger as a result, so per-share comparisons across periods need care.
Working-capital build: non-cash current assets rose about 91% (from about $3.0B to $5.8B) against 22.5% revenue growth. I can't tell from these tools how much is inventory, receivables or investments. The 10-K needs checking.
Current liabilities rose $741M in Q4 alone (from $2.1B to $2.85B). The composition is unknown, so check for current debt.

4. Cash flow¶

$M	FY23	FY24	FY25	FY26
Operating cash flow	634	546	634	80
Capex	436	347	441	1,103
FCF (OCF − capex)	198	199	193	−1,023
Investing CF	−5,929	−351	−414	−1,414
Financing CF	3,554	758	−452	+1,477

Operating cash flow collapsed. It fell 87% while GAAP net income was $787M. Cash conversion was about 10%. Q3 FY26 operating cash flow was negative (about −$94M), and derived Q4 was only about +$70M.
Capex more than doubled. It went from 7.6% of revenue in FY25 to 15.5% in FY26. Q4 capex was about $556M, roughly double Q3's $289M. That suggests a heavy capacity build.
Funding: the FCF shortfall was covered by the equity raise and the cash balance. Cash was $1.59B at Mar-26 and $1.16B at Jun-26.
FCF definitions differ. The fundamentals feed shows −$650M, while OCF minus capex from the annual statement gives −$1.02B.

5. Insider activity¶

Selling dominates, and there are no open-market buys after Nov-2024. - No filings in the past 7 days. The latest is 2026-09-11, and the price then was about $306. - Open-market sales: my tally is about $42M of sales since late Oct 2025, excluding Bain. I counted the 3/6/26 Digirolomo row once because it appears duplicated. The only purchases in the dataset are CEO Anderson's two 500-share buys (about $103K total) in Nov–Dec 2024. - Recent cluster (Aug 18 – Sep 11, 2026): seven sales totaling about $8.2M at $268–$324. Sellers were CTO Eng ($3.58M), Director Digirolomo ($1.63M plus another $0.63M on 8/31), CFO Luther ($0.97M), Directors Neal-Graves, Skaggs and Beard (the last at about $0.15M). - CFO Luther has sold roughly monthly (Feb, Apr, May, Jul, Aug 2026). That looks like a pre-arranged plan, though the data doesn't confirm it. - Director Xia repeatedly exercises options and sells, which also looks routine. - Large sales earlier: - Barbarossa (officer): $9.7M at $160 on 11/6/25 and $8.4M at about $141 on 10/29/25. - Corasanti (director): $2.95M at $196.74 on 12/10/25. - Bain Capital (>10% holder): sold 7.5M shares at $143.37 (about $1.08B) on 2025-11-07. A filing line shows 7,754,252 shares afterward, which I read as its remaining stake (about $1.8B at ~$237). That is a possible overhang. - Equity awards: annual grants on 8/28/26 went to the CEO (30,564 shares), CTO, CFO and others. These are compensation, not buying signals. - Context: $42M is tiny against a $46.7B market cap. Most sales appear routine or plan-based, but there is no insider buying support.

6. Key takeaways¶

Positives 1. Revenue growth is accelerating, with a derived Q4 at about +34% year over year. 2. Gross margin has expanded for five straight quarters, to about 38.5%. 3. GAAP profitability has turned, with FY26 EPS of $4.12 against −$0.52 a year earlier. 4. The balance sheet was strengthened by the preferred conversion and the equity raise, with a 2.4x current ratio and moderate leverage.

Risks and watch items 1. Cash conversion: a 10% OCF/NI ratio plus a $1.1B capex program means FCF is deeply negative. The key question is whether working capital and capex normalize. 2. Valuation and volatility: 57.6x GAAP P/E, about 34x EV/EBITDA, and a beta of 2.1. The stock is already about 20% below its 50-day and 200-day averages. 3. Forward-EPS comparability: the $13.92 forward EPS likely isn't on the same basis as GAAP EPS. 4. Dilution and overhang: the preferred conversion, the equity raise and Bain's remaining stake. 5. Current liabilities jumped in Q4, and the composition is unknown. 6. Insider selling is persistent, with no buying.

Next checks - Items in the FY26 10-K: inventory and receivables, debt maturities, share count and the adjusted-versus-GAAP EPS bridge. - The next quarterly report (quarter ending Sep 30, 2026). I expect early-to-mid November based on last year's pattern, but the tools give no earnings calendar.

Summary table¶

Category	Key point	Data / evidence	Read-through
Valuation	Rich on trailing numbers	P/E 57.6x, fwd P/E 17.1x, EV/EBITDA ~34x, P/B 4.26	Priced for continued growth and execution
Price context	Implied ~$237	52-week range $112.96–$440, 50-/200-day avg ~$295	Pulled back about 20% below trend averages
Growth	Accelerating	FY26 revenue $7.12B (+22.5%), derived Q4 ~$2.05B (~+34% YoY)	Strong demand momentum
Margins	Expanding	Gross margin 31% (FY24) → 37.5% (FY26) → ~38.5% (Q4)	Positive operating leverage
Earnings	Turnaround	FY26 NI $787M, EPS $4.12 vs FY25 EPS −$0.52	GAAP profitable, but ROE only 8%
Cash flow	Major weakness	FY26 OCF $80M, capex $1.10B, FCF ≈ −$1.0B	Funded by equity and cash
Balance sheet	Stronger but larger	Equity $10.9B (+93%), cash $1.16B, current ratio 2.43, D/E 0.32x	Preferred converted and equity raised (inferred)
Working capital	Large build	Non-cash current assets +91%, current liabilities +59%	Needs 10-K detail
Insider activity	Selling, no buying	~$42M of sales since Oct-25, none in the last 7 days, last sale 9/11/26 at ~$306	Mostly routine, no insider support
Large holder	Bain overhang	Sold 7.5M shares at $143.37 (~$1.08B) on 11/7/25, ~7.75M remain	Possible future supply
Data caveats	Mismatches	FCF −$650M vs −$1.02B, NI $770M vs $787M, Q4 figures derived	Confirm with filings before relying on them

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for COHR: A 30% Air Pocket in a Business That Is Accelerating

I'll start with the bear's best card, the chart. COHR is down 29.8% in 11 sessions and 44% from its June high. I'm not going to pretend that didn't happen. But the fundamentals moved the other way.

1. The business is accelerating, and the price isn't telling you that¶

	FY24	FY25	FY26
Revenue	$4.71B	$5.81B	$7.12B
Gross margin	30.9%	35.2%	37.5%
Net income	-$159M	$30M	$787M
Diluted EPS	-1.84	-0.52	+4.12

Growth is picking up. By my arithmetic, YoY revenue growth went from 17% in Q1 to roughly 34% in Q4, and sequential growth went from 3% to about 13%. The Q4 figures are derived (FY minus the first three quarters), not reported, but the direction is clear.
Margins are widening as revenue scales. That is operating leverage, not just a demand spike.
The price is still well above where it was. A year ago COHR closed at $120.79. At $237 the stock has roughly doubled, while the business went from a loss to nearly $800M of profit.

The 30% drop in 11 sessions also came with no new fundamental bad news. The latest financials are unchanged, and the company-specific headlines in the window were constructive: the 3M/Amazon data-center deal, TrendForce's AI fiber shortage running through 2028, and COHR +2% in an optics rally. The selloff tracks sector headlines like IBD's "Chip Stocks Tumble On AI Investment Worries," plus a Susquehanna target cut. That looks like de-risking, not a broken thesis.

2. The valuation argument cuts both ways¶

The bear will cite 57.6x trailing GAAP P/E. That multiple sits on earnings from the first year of a turnaround, so it overstates the price you're paying. The derived Q4 EPS of about $1.20 annualizes to about $4.80, which is already about 49x at today's price and falling each quarter.

The 17.1x forward P/E on $13.92 forward EPS probably uses adjusted earnings against GAAP trailing, so I won't lean on it. As a sensitivity, even if forward earnings came in at half that figure, you'd pay about 34x for a company growing in the 30s with expanding margins. The PEG is 0.92. That is not cheap, but it isn't a bubble multiple either.

Susquehanna's cut to $350 from $425 gets cited as a negative. But $350 is still about 47% above spot, so the analyst who trimmed the target still sees large upside.

3. The cash flow problem is real, but I read it as a growth signal¶

This is the bear's strongest point, so I'll take it head on. FY26 operating cash flow was $80M, capex was $1.1B, and free cash flow was about -$1.0B (the feed shows -$650M, so the definitions differ).

Here is how I read it: - Capex is capacity. It went from 7.6% to 15.5% of revenue, and Q4 capex of about $556M was roughly double Q3's. Management is building ahead of a supply-constrained market. - Working capital is consistent with a demand build. Non-cash current assets rose about 91%. I can't split that into inventory and receivables without the 10-K, so this part is inference. Building inventory ahead of a shortage is a different story from building it into a demand collapse. - The balance sheet absorbs it. Equity doubled to $10.9B, the current ratio is 2.43, D/E is 0.32x, and net debt is about 1.6x EBITDA. There is no solvency question here.

I'll concede this much: if operating cash flow doesn't recover in the coming quarters, the bear gets a stronger case. That is the number to watch.

4. The "overhangs" are smaller than they look¶

Insiders: About $42M of sales since October 2025 against a $46.7B market cap is under 0.1%. Much of it looks routine, such as CFO Luther's roughly monthly sales and option exercises. Several of the big sellers sold at $141–$160, far below today's price, and held on through the rally.
Bain: Its remaining ~7.75M shares are about 4% of the company. It sold at $143.37, and the stock is now 65% above that. This is a real but bounded overhang.
Dilution: The preferred conversion and equity raise already happened. The capital structure is cleaner than a year ago.

5. The technical setup favors a bounce¶

Support has held three times. The 215–222 zone was tested on 3/30, 7/29 and 10/20, and the lower Bollinger band at 215.09 sits inside it. The first two tests were followed by rallies to 347 and 379. That's two episodes, not a law, but the buyers are showing up at the same level.
Selling pressure is easing. The daily TD Sequential completed a 9 buy setup, the MACD histogram narrowed for the first time, and volume faded from 9.95M to 6.15M over the last three sessions.
The monthly regime is intact. The monthly SuperTrend is still UP, with its stop at 228.68. The October 20 intraday low of 217.83 went well through that line, yet the stock closed at 231.80 and 237.37 today.
The first targets are close. The gap fill and 10-EMA at 252–262 are about 9% away. The 287–295 cluster is about 23% away.

The weekly SuperTrend is down with its stop at 395.74. That is a lagging indicator of the June–October decline. It tells you the stock fell, not that the business stopped growing.

6. The macro backdrop is a headwind, not a thesis-breaker¶

Polymarket has an 86% chance of a hold at the October FOMC, only 8% for a recession by year-end, and 9% for an AI bubble burst in 2026. Higher-for-longer pressures the multiple, but a demand shock is what would break the thesis, and the evidence doesn't show one. Hyperscaler earnings, COHR's own November report (date unconfirmed) and NVDA around November 18 are all potential catalysts.

Where I could be wrong¶

A month-end close below 228.68 would flip all three SuperTrend tiers down, and a break of 215 opens the 170–210 range. That's the invalidation line. ATR is about 8.8% of price, so sizing matters. The risk is roughly 8–9% down to support against 9% to the gap and 23% to the cluster, with a $350 analyst target as the longer-term upside.

Bear, here's my question. The stock fell 30% in 11 sessions while revenue growth went from 17% to roughly 34% and margins expanded for five straight quarters. What specifically in the company's numbers justifies treating this as a broken thesis rather than a sector flush? If your answer is cash flow, tell me what OCF level would change your mind. Bull Analyst: # Bull Rebuttal: What I Concede, Where You Overreach, and the One Test That Matters

Bear, you landed real hits. I'll start with what I'm giving up, then show where I think you overreach, then answer your OCF question with thresholds of my own.

What I concede¶

The PEG and the $13.92 forward EPS are out. You can't dismiss one and keep the other. The honest valuation is the Q4 run-rate: about 49x on derived EPS, and about 52x on market cap over annualized derived net income ($223M × 4). That is a full multiple.
228.68 is the wrong invalidation line. At 0.41 ATR it sits inside the noise. I'm moving mine to a close below 215, the bottom of the support zone and the lower Bollinger band. The primary trend is down, and I'm not arguing otherwise.
The bounce evidence is thin. The TD-9 is daily only, RSI shows no divergence, OBV is at its window low, and today's volume bar is partial. I have a setup, not a confirmation.
I cherry-picked the macro. Rates are a real headwind for a beta-2.1 stock. The one-week direction was less hawkish (October hike odds fell 20.5 points), but the regime is still higher for longer.
"Insiders sold at $141–160" was stale. The August–September cluster was $8.2M at $268–324. That is still about 0.02% of market cap, and we agree the blackout makes the last three weeks uninformative.
The operating-income-to-net-income gap is a real question. I can't bridge 11.8% operating margin to $787M of net income either. Quarterly net income of $226M, $147M, $191M and about $223M isn't smooth, and Q1 was highest on the lowest revenue. That suggests below-the-line items. It goes first on the 10-K checklist.
The capex ramp is a trend, not a spike. By my arithmetic it went from about $129M a quarter in H1 to $289M to about $556M.

Where I think you overreach¶

1. "Accelerating rests on one derived number." It doesn't. The three reported quarters already accelerate without Q4: YoY growth of 17.3% → 17.5% → 20.6%, and sequential growth of 3.4% → 6.6% → 7.1%. Comparing quarterly YoY to FY25's 23.4% mixes periods, and FY25 grew off a base that had fallen 8.8%. FY26 grew 22.5% on top of that, which is about 51% over two years.

Your own case also leans on derived Q4. The $556M capex, the $70M OCF, the $741M jump in current liabilities and the 2.4-quarter runway all come from the same subtraction (FY minus nine months) you call unverified when it produces 34%. Either Q4 is usable or it isn't. The reported FY26 OCF of $80M is solid, and I accept that it is the core of your case.

2. The runway math. The 2.4 quarters assumes Q4 capex (27% of revenue) repeats and that cash is the only liquidity. Leverage is the other half of the picture: net debt is about 1.6x EBITDA. At 3.0x, which I'm using only as an illustration with no covenant data, that is roughly $2B of debt capacity. Debt markets at that leverage don't hinge on the equity price the way you suggest. Derived OCF also improved from about -$94M in Q3 to about +$70M in Q4 while revenue rose roughly 13% sequentially. The level is inadequate, but the direction isn't the one you describe.

3. The growth bar is lower than "priced for perfection" implies. Holding FY26's 22.5% growth in FY27 needs only about 2.5% sequential growth per quarter off the Q4 exit rate. Flat sequential revenue still gives about +15%. Q4's roughly 13% may include timing, so I wouldn't extrapolate it. On that 22.5% case, net margins of 11–13% put the stock at roughly 41–49x FY27 GAAP earnings. That is not cheap, but it is a multiple the business can earn into if it delivers.

4. "No capitulation, and retail is already long." An RSI of 33 and z-scores near -1.5 after a 30% fall are partly artifacts of expanding volatility, and the technical report says so about the z-score. On positioning, the sentiment report shows 3 of the 9 bullish tags come from one account, 21 of 30 posts are unlabeled, and other posters are sitting in cash. A few call buyers are not a crowded trade. I won't use "zero bearish labels" as evidence either.

5. The lagging-trend argument has a price. The weekly SuperTrend flips up only on a close above 395.74, which is about 67% above spot. It describes the decline but can't be used for entry. "Wait for evidence" isn't free: the gap fill at 252–262 could happen before the print.

6. Susquehanna. Fair, the cut was name-specific, and I'll stop calling this a pure sector flush. Beta of 2.1 and the unverified claim about the market sorting component suppliers by margin profile fit your reading. But the rationale for the cut isn't in our data, so neither of us should build on it.

Your OCF question, answered with a three-zone test¶

September-quarter result	My reading
OCF ≥ ~$225M, capex ≤ ~$556M	Your test passed. Cash conversion thesis confirmed, so I'd add.
OCF between ~$70M and $225M, capex ≤ ~$556M	Improving but not repaired. Hold size and don't add.
OCF ≤ ~$70M with capex ≥ ~$556M	I agree "capacity" becomes a funding story at 49–52x. Thesis impaired.

Alongside OCF, I'd want sequential revenue growth of at least about 2.5%, gross margin around 38% or better, a 10-K split of the working-capital build, and the bridge from operating income to net income.

The trade as I'd frame it: a starter position here, sized for an ATR of about 8.8%, with a closing stop below 215, which is about 8–9% of risk. The upside is about 9% to 252–262 and about 23% to the 288–295 cluster, and the position gets added to only if the print clears the top row.

My question back: if OCF lands in the middle zone, which is the most likely outcome given Q3 → Q4, what does your framework do? And if the stock fills the 252–262 gap before the print, are you still waiting? Bull Analyst: # Bull Closing Rebuttal: What's Left Is Timing and Sizing, Not the Business

Bear, we now agree on most of this. Revenue is accelerating in the reported quarters. Margins are expanding. There's no solvency issue. The stock is full at roughly 50x run-rate. The primary trend is down. Cash conversion is the test. Two disputes remain: whether a sized starter before the print is defensible, and what the cash flow has to show to pass.

What I concede¶

My table had holes. OCF of $60M with capex of $500M fits no row. The bottom row needs an "or," and I fix it below.
Q4 FCF got worse. It went from about −$383M to −$486M. I cited OCF improving by $164M, but capex rose $267M, and funding depends on the net figure.
My "add" row still burns cash. At $556M of capex it is −$331M. Calling that "confirmed" was too generous.
Capex should be measured on an accrual basis. If the $741M jump in current liabilities includes capex payables, cash capex catches up next quarter.
52x used the friendlier net income. On $770M instead of $787M, derived Q4 is about $206M, or about 57x. My range is 52–57x.
At $257 I wouldn't chase. The multiple is about 57x with no new information, and the 215 stop is 16% away against 12–15% to the cluster. I'd trim into the gap, not add.
A closing stop doesn't survive an earnings gap. I'll size to the gap, not the ATR. Two ATRs below is about $195, roughly 18% lower.
The "three tests of support" record is regime-dependent. The first two tests came with the weekly trend up and the 50-SMA above the 200-SMA. That support zone marks where I'm wrong. It isn't why I'm buying.
Net margin hasn't tracked gross margin since Q3. Incremental net margin was 37% from Q2 to Q3 but only about 13% from Q3 to Q4, versus a 10.6% average. That is still positive, but it fits depreciation catching up with the capex ramp. I'll stop calling Q4 net-line operating leverage.

Where I hold the line¶

1. Waiting isn't a free option. You say buying now costs me the choice after the evidence. But on a binary print the evidence arrives through the gap. If the print is good, you buy at the post-gap price, which could be 57–60x, higher than the 49–52x you're objecting to now. If it's bad, you save the loss. That is variance reduction, which is legitimate, but it isn't information at a pre-print price. The tool for variance is size, and I'll size the starter so a 20% adverse gap costs about 0.5% of the portfolio (roughly a 2.5% position).

2. The "low bar" holds on your base too. - On the derived Q4 base of $2.05B, +22.5% needs about 2.5% sequential growth per quarter. - On your $1.93B illustration it needs about 5%. - Both are below the reported 6.6% and 7.1% in Q2 and Q3. - You used derived Q4 for your capex and OCF numbers, so it can't be reliable for your side and "timing" for mine. It might include timing, and that is exactly why I gave a range.

3. Capex is both a cost and an asset, and your test treats it only as a cost. As a rough sanity check (derived, gross profit rather than cash, not a return on capital), Q4 gross profit annualizes to about $3.15B versus about $2.05B in FY25. That is about $1.1B more, against FY26 capex of $1.10B. It is far from proof, but the build isn't obviously value-destroying.

Your ceiling of capex at or below Q3's $289M would require capex to roughly halve. Both the news and sentiment reports describe optical supply as tight through 2028. In that market, halving capex means growth is ending, which contradicts the acceleration you've conceded. I'd test intensity and productivity instead.

4. Your 70x is TTM logic. It puts a $670M "core" earnings figure under a stock that is growing, when the TTM includes an H1 at roughly half Q4's earnings. You rejected TTM P/E for the same reason when I used it. The bridge from operating income to net income still goes first on the 10-K checklist. Any non-recurring item in Q4 itself would hurt my run-rate, and I won't pretend otherwise.

5. A monthly SuperTrend flip is a flag, not an exit. A close below 228.68 means I stop adding. My exit is a close below 215. The weekly has been down for months, so the monthly flipping adds little information beyond the price decline we've both already seen.

Your question: the $741M¶

Does the top row still say "add" on $225M of OCF if the $741M is mostly operating payables or customer deposits? No. - If it's operating payables, Q4's $70M of OCF had up to $741M of help, and underlying OCF was deeply negative. A $225M reading would then need to be measured before that stretch. - If it's customer deposits, it is demand evidence but also a liability that reverses as product ships. I'd count it as timing, not conversion. - If it's capex payables, OCF is clean, but cash capex steps up. That is why accrual capex is the number to use.

The supplemental cash-flow note on capex in payables and the payables roll-forward answer this before I add anything.

Revised test:

September-quarter result	Action
OCF ≥ ~$225M excluding any payables or deposit stretch, and accrual capex ≤ ~17% of revenue (~$350M)	Add
Anything between	Hold, no add
OCF < ~$70M, or accrual capex ≥ ~$500M with sequential revenue growth < ~5%	Thesis impaired, exit

The $350M ceiling is above your $289M, close to FY26's 15.5% average intensity. I'm not asking the company to stop growing, but I'm asking it to stop spending 27% of revenue.

Bottom line¶

My position is a gap-sized starter with no add above $257, a trim into 252–262 or the 288–295 cluster, a close-below-215 exit, and add/exit decisions made on the table above. The stock has de-rated about 30% since Oct 6 with no change in the fundamental data. At about 50x run-rate it's expensive, but it's priced after a de-rating, for a business whose reported growth is still accelerating.

My question back: if the print lands in my top row, with clean OCF at or above $225M and capex intensity back near 17%, and the stock gaps to $270 (about 60x run-rate), do you buy? If yes, waiting is a price you've already agreed to pay. If no, what evidence would ever get you in at that multiple? Bull Analyst: # Bull Final Response: We're Down to the Price of an Option

Bear, you've narrowed this to one question: does a small position go on before the print or after? We agree on the business, the test and the exits, so I'll take your hits first and then say where I still disagree.

What I concede¶

My two add rules collided. The table says "add" on a clean print, but my bottom line says "no add above $257." Fix: the gate should be a multiple, not a price. No adds above about 57x annualized latest-quarter GAAP net income. At $270 (about $53B market cap), that needs September-quarter net income of about $233M. That is +4.5% on the derived $223M, or +13% on the $206M implied by the feed's $770M. The print decides whether $270 clears the gate, not a price I wrote down in advance.
Turns belong in the top row. I'll add inventory days and DSO flat or better. OCF of $225M can otherwise be reached by stretching payables.
The starter is a tactical option, not the thesis. At 2.5%, a 14% win is about 0.35% of the portfolio. I'll stop implying it's more.
Gross profit isn't earnings. Incremental gross margin Q3→Q4 was about 45% (+$108M on +$239M of revenue, all derived). Net income captured only about $32M of that. I'll defend the gross-line leverage and leave the net line to the 10-K bridge.
Read the filing now. You're right that the $741M current-liability jump, the inventory and receivables split, the capex-payables note and the operating-to-net-income bridge are public today. I'm moving that step ahead of any buying.

Where I hold the line¶

1. Your breakeven compares my stress case to a central case. The 1.45x odds ratio pairs a +14% good gap with a −20% bad gap. I gave you 20% to size the position, not as an expected bad-state move. With a symmetric ±14%, breakeven is 1:1. The question then becomes whether a good reaction is at least as likely as a bad one. The stock has also already fallen 30% in 11 sessions with no change in the published numbers.

2. Table rows aren't price outcomes. You said yourself the stock can rally on a guide despite weak cash. The print moves the stock on revenue, margin and guidance as well as OCF. Mapping "top row" to up and "bottom row" to down, then counting conditions, tests my add rules, not the odds of the gap.

3. "Growth consumes cash" isn't this company's record. FY25 revenue grew 23.4%, yet OCF was $634M, or 10.9% of revenue. FY26 broke that pattern, and whether it's a one-off build is the open question. But the top row asks for about 11% OCF margin, which is what COHR has done in a growth year before.

4. The capex ceiling is intensity, not a halt. At 17% of a $2.1–2.3B quarter, the ceiling is about $357–391M. That is roughly a third below Q4's $556M, not a halving, and it is still above FY25's 7.6%. Capex that leads revenue should normalize as the added capacity is absorbed. If management is still spending at 27% of revenue, the top row fails. That would mean the growth thesis may be right while the funding and multiple thesis is wrong, and I'd sit in the middle row without adding.

5. Your working-capital numbers don't reconcile. You cite about $1.1B "by elimination" (the $1.34B EBITDA-to-OCF gap less your interest estimate) and about $1.7B from the balance sheet. That ~$0.6B difference suggests some of the current-asset growth never ran through OCF, though interest, taxes and SBC are all estimates. I'd treat the balance-sheet figure as an upper bound. The cash-flow statement's working-capital lines settle it.

The revised plan¶

Step	Action
1. Before buying (now to about Oct 28)	Read the FY26 10-K for four items: composition of the $741M, the inventory/receivables split and aging, capex in payables, and the operating-income-to-net-income bridge. If the $741M is mostly operating payables or deposits, or receivables look concentrated or aging, no starter. That converts to your "wait."
2. If it clears	Starter of 2.5% or less, sized so a 20% gap costs about 0.5% of the portfolio. Exit on a close below 215. No adds if October closes below 228.68.
3. After the print (likely early-to-mid November, date unconfirmed)	Add only if OCF ≥ ~$225M ex-stretch, accrual capex ≤ ~17% of revenue, turns flat or better, and the multiple is ≤ ~57x annualized. Hold in between. Exit if OCF < ~$70M, or accrual capex ≥ ~$500M with sequential growth < ~5%.

Bottom line¶

Revenue is accelerating in the reported quarters, gross margin has expanded for five straight quarters, and there is no solvency issue. The open item is cash conversion, and the stock is full at 52–57x run-rate in a downtrend. I concede all of that.

Your plan pays up to 60x for proof. Mine pays about 50x for a small, defined option on the same business after a free filing check, and still pays up for proof if it arrives. I'm no longer asking you to buy the promise. I'm saying a 2.5% option is a reasonable price for a stock 30% cheaper than 11 sessions ago on unchanged published numbers, as long as the 10-K doesn't show the cash problem is worse than it looks.

Bull stance: conditional starter buy. It is gated on the 10-K read, sized to the gap, and exited on a close below 215. Adds are earned by the September-quarter cash-flow statement. Bull Analyst: # Bull Close: The Disagreement Is About the Price of an Option, and I'll Shrink It

Bear, your final round is fair, and most of it lands. I'll concede what's right, hold the line on three points, and then offer a plan that removes most of what's left between us.

What I concede¶

Down from the peak isn't a margin of safety. On derived Q4 annualized net income of $892M, $338 was about 75x and $237 is about 52x. Even my 215 stop is about 47x, so it's a chart level, not a valuation floor.
The filing read is a screen, not an edge. It can rule out a bad composition of the $741M. It can't tell me September-quarter OCF.
Your working-capital floor is the better working number. NI of $787M plus about $580M of D&A against $80M of OCF implies roughly $1.3B absorbed, which exceeds the whole $1.1B capex program. SBC pushes that figure up, and any non-cash gain inside the $787M pushes it down. The cash-flow statement settles it. Composition matters more than capex.
The top row isn't self-funding. At $225M of OCF and $357–391M of capex, FCF is about −$130M to −$165M a quarter.
A symmetric gap means the print gives no edge. At ±14% the breakeven odds are 1:1, and nobody can claim to know which side of that the print lands on.
The starter is tactical. At 2.5%, the whole dispute is about ±0.4% of the portfolio.

Where I hold the line¶

1. The hurdle did change, even though 52x isn't cheap. I'm not calling it cheap. I'm saying the growth you must underwrite is lower than 11 sessions ago. This is illustrative, with FY27 at +22.5% revenue ($8.72B), net margins of 10.9–13%, and a flat share count:

Price	Market cap	FY27 P/E at 10.9% margin	at 13% margin
$338 (Oct 6)	~$66.6B	~70x	~59x
$237 (today)	~$46.7B	~49x	~41x

The same fundamentals now need less to be right. You've also been consistent that growth isn't your objection, and the reported quarters (YoY 17.3% → 17.5% → 20.6%, sequential 3.4% → 6.6% → 7.1%) back that up.

2. The funding burn is manageable. Even at −$150M a quarter, a year of burn is about $600M. Added to $2.3B of net debt, that is about 2.0x trailing EBITDA, up from 1.6x. At an assumed 5.5%, the extra interest is about $33M pre-tax, roughly 4% of annualized NI. It isn't free, but it's a drag on the multiple, not a thesis-breaker. The big equity raise has already happened.

3. The filing read does move the odds on the cash cycle. If the build is inventory, OCF should snap back as it sells through. If it's receivables or payables stretch, it won't. That is what my gate screens for, and your plan uses the same gate to go from "no" to "small." Neither of us has read the filing yet, so both plans are conditional on it.

Where we converge¶

Your retest idea is good. A hold at 215–222 on expanding up-day volume cuts the stop distance to 3–5% and supplies the confirmation the technical report said it lacks. I'd fold it in and split the starter, which cuts the pre-print exposure in half:

Step	Action
1. Now to ~Oct 28	Read the 10-K and March 10-Q for four items: composition of the $741M, the inventory/receivables split and aging, capex in payables, and the operating-to-net-income bridge. If the $741M is mostly operating payables or deposits, or receivables look concentrated or aging, no position.
2. If it clears	First half: ~1.25%. A 20% gap costs ~0.25% of the portfolio. Exit on a close below 215. No adds if October closes below 228.68.
3. Second half	Added on either of two triggers: (a) a retest of 215–222 that holds with volume expanding on up days, or (b) a clean September print. A clean print means OCF ≥ ~$225M ex-stretch, accrual capex ≤ ~17% of revenue, turns flat or better, and a multiple ≤ ~57x annualized (about $233M of quarterly net income at $270).
4. Hold or exit	Hold, no add, in between. Exit if OCF < ~$70M, or accrual capex ≥ ~$500M with sequential growth < ~5%.

This doesn't require the gap fill. At $257 I trim rather than add, as before.

Bottom line¶

Bull stance: conditional, half-sized starter before the print, with the rest earned by evidence.

The case still stands on what's reported: - Revenue growth is accelerating. - Gross margin has gone from 36.6% to 37.6% across the three reported quarters, and the derived Q4 is about 38.5%. - Net income swung from −$159M to +$787M in two years. - There is no solvency question. - News flow points to an optical supply crunch through 2028. That's TrendForce via headlines, unverified, but it fits margins rising alongside growth.

The open item is cash conversion, and I've committed in advance to what passes, what holds and what makes me exit. If September OCF comes in near $70M on capex near $556M, I'll say the thesis broke at the cash line.

You'd pay up to 60x for proof, and I'd pay about 50x for a small, defined option and then pay up for proof too. After this exchange, that difference is a question of sizing, not of what the business is.

Bear Researcher¶

Bear Analyst: # Bear Case for COHR: The Business Is Growing, the Cash Isn't, and the Price Still Assumes It Will

You asked what in the numbers makes this a broken thesis rather than a sector flush. Nothing does, and I don't need it to. My case rests on three points: - The growth hasn't turned into cash. - The price still capitalizes a cash recovery that hasn't happened. - The next three weeks carry more event risk than your 8-9% downside suggests.

1. This isn't an 11-session air pocket¶

The intraday highs run 440.00 (6/3), 439.68 (6/22), 391.37 (8/7) and 341.76 (10/5). That is four months of lower highs. The weekly SuperTrend, which the tool treats as the primary trend, is down with its stop at 395.74. The stock was already 21% off its high on October 6. Only the last leg was fast.

"No new bad news" doesn't make the stock cheap. At $237 it still trades on 57.6x GAAP earnings, 4.26x book and about 34x EV/EBITDA.

Your "company-specific" headlines are weaker than they look. The 3M/Amazon item was a 3M deal where COHR "edged higher" in sympathy. The +2% was a one-day optics rally in the middle of the slide.

2. "Accelerating" rests on one derived number¶

Reported YoY growth was 17.3%, 17.5% and 20.6%, all below FY25's 23.4%. FY26 grew 22.5%, slightly slower than FY25. The 34% is FY minus nine months, a residual with no reported figure behind it, as you said yourself.

In that same quarter: - Capex doubled to about $556M. - Current liabilities rose $741M. - OCF was about $70M on roughly $2.0B of revenue.

I'm not saying the revenue is fake. I'm saying your best growth datapoint is the least verified one, and it sits next to the worst cash flow.

One reconciliation I can't make from the feed: 11.8% operating margin on $7.12B is about $840M of operating income. After interest on roughly $3.45B of debt (even at 5%, about $170M), I can't get to $787M of net income without a tax benefit or non-operating item. That's the first thing I'd check in the 10-K. If any of it is non-recurring, 57.6x flatters the stock.

3. Cash flow: your reading and mine predict different things¶

FY26 OCF was 1.1% of revenue, against 10.9-12.3% in FY23-FY25. You read the working-capital build as inventory ahead of a shortage, but you also said you can't split it from receivables. Both readings are inference. They make different predictions: - If it's inventory, OCF should snap back as it sells through. - If it's receivables or product that isn't turning, it won't.

The stock is priced for the first outcome.

"The balance sheet absorbs it" is also thinner than it sounds. Cash fell from $1.59B to $1.16B in one quarter, after what looks like a roughly $1.85B equity raise the quarter before (inferred from financing flows). At the Q4 pace (OCF about $70M, capex about $556M, FCF about -$486M), $1.16B is about 2.4 quarters of runway before new financing. I don't have the revolver capacity, so that's a ceiling on my certainty, not a forecast.

I agree there's no near-term solvency problem. But "not insolvent" isn't "self-funding," and a company that needs capital markets depends on its stock price and on rates. Equity doubled to $10.9B, yet ROE is 8.0% and ROA is 3.4%. That is a bigger balance sheet, not a better one.

Operating leverage also cuts both ways. $1.1B of capex brings depreciation with it. If growth slips back toward the high teens, there's a larger fixed-cost base to cover.

4. Valuation: your own math lands at 49x¶

You annualized Q4 to $4.80 and got 49x. Then you softened it with a hypothetical of half the forward EPS, which you picked. Reaching $6.96 needs about 45% growth beyond the Q4 run-rate. The $13.92 needs about 2.9x. You can't dismiss $13.92 as non-comparable and keep the 0.92 PEG, which almost certainly rests on the same consensus growth.

On Susquehanna, "still 47% above spot" misses a detail. The same note raised AMD and QCOM and cut COHR. That is a stock-specific reduction inside a constructive chip note, which cuts against "sector flush." The rationale isn't in our data. Targets also lag price, so this cut is hardly a sign analysts know where the floor is.

5. Technicals: your invalidation line is inside the noise¶

The monthly stop at 228.68 is $8.69 (3.7%) below the price. That is 0.41 of an ATR, with ATR at 8.8% and about seven sessions left in October. The technical report itself says stops inside one ATR are likely to be hit by normal noise. The FOMC on Oct 28-29 lands just before the month-end close, and a close below the stop turns all three SuperTrend tiers down.

You also treat the monthly SuperTrend as proof of health and dismiss the weekly as "lagging." They are the same indicator with the same lag. The monthly is simply the slowest, so it flips last. The tool's rule is that the higher tier wins, and the weekly is down.

The bounce evidence is thin: - TD Sequential: the 9 is daily only. Weekly is +2 and monthly +3, and the tool calls it a tactical watch. - MACD: the histogram narrowed once, on a bar with 3.05M volume that may be incomplete. - RSI and OBV: RSI is flat at 33-35 with no divergence. OBV is near its window low. - Volume: fading volume on a bounce isn't confirmation. The tool says it needs expansion on up days. - No capitulation: RSI never reached 30, and z-scores are only -1.4 to -1.6. Meanwhile retail is already buying Feb 2027 $300 calls, so positioning is bullish before any washout.

On the three tests of support, the first two came with the weekly trend up and the 50-SMA above the 200-SMA. Now the 50 is below the 200 and the weekly is down. Repeated tests also tend to consume the bids sitting at that level. That's a general pattern, not a law.

The payoff is lopsided. You get about +9% to the gap, then a four-way resistance stack at 288-295. If 215 fails, the last real structure is 170-210, which is 11-28% lower.

6. Overhangs and macro¶

I'll concede Bain. 7.75M shares is about one day of volume, so it's bounded. But "insiders sold at $141-160" is stale. The latest cluster (Aug 18-Sep 11) was seven sales, about $8.2M at $268-$324, including $3.58M from the CTO. That is 13-36% above today's price. Insiders probably can't buy right now because of the pre-earnings blackout, so I'm reading nothing into the last three weeks.

On macro, you quoted the 86% hold but left out: - 12% odds of an October hike. - 97% odds of no cuts in 2026. - 80% odds of another hike by Dec 10 (thin market). - AI-bubble odds up 3.1 points on the week.

A beta-2.1 stock on 57x is in the wrong rate regime for that.

Your question: what OCF would change my mind¶

FY23-FY25 OCF ran 11-12% of revenue. On a roughly $2.05B quarter, that is about $225M. Here is what I'd need to see: 1. September-quarter OCF of at least about $225M, with capex no higher than Q4's level. 2. A 10-K split showing the working-capital build is ordinary inventory and receivables, not concentrated or aging.

If OCF repeats Q4's roughly $70M, "capacity" becomes a funding story at about 49x. Until the November print, the FOMC and the month-end close resolve this, I'd rather wait for evidence than pay for the recovery in advance. Bear Analyst: # Bear Rebuttal: Your Test Passes a Cash Burn, and the Stop Won't Hold Through the Print

You gave up a lot: the PEG, the 228.68 line, the macro cherry-pick, the stale insider point. I'll return the favor, then answer your two questions directly.

What I'll concede¶

Acceleration is real in the reported quarters. YoY growth of 17.3% → 17.5% → 20.6% and sequential growth of 3.4% → 6.6% → 7.1% don't need Q4. I overstated that. I never disputed that revenue is growing, though. The dispute is what each marginal dollar costs.
I used derived Q4 too. My cash case doesn't depend on it, though. The reported FY26 figures are OCF $80M against $787M of net income and $1.10B of capex. The derived quarter only places the timing within the year.
Positioning is out of my case. One account supplies a third of the bullish tags, and I leaned on a single call buyer. The tape doesn't need it.
Debt capacity buys time. At Q4's burn of about $486M a quarter, your illustrative $2B covers roughly four quarters, not 2.4. My runway figure was too tight. Solvency was never my point. The point is what a levered build does to a 50x multiple, with 97% odds of no cuts and 80% odds of another hike by December.

1. Your table passes a cash burn¶

Your row	OCF	Capex ceiling you allow	FCF at that ceiling
Top ("add")	≥ $225M	$556M	≥ −$331M
Middle ("hold")	$70–225M	$556M	−$486M to −$331M
Bottom ("impaired")	≤ $70M	≥ $556M	≤ −$486M

Your "cash conversion confirmed, I'd add" row still burns $331M in a quarter. At $556M of capex, breakeven needs OCF of about 27% of revenue, against the 11–12% history. The table also has holes. OCF of $60M with capex of $500M fits no row, so the bottom row needs an "or."

You also read the improvement from −$94M to +$70M of OCF as the right direction. On the metric that matters, FCF went from about −$383M in Q3 to about −$486M in Q4. That is $100M worse. The $70M also sits next to a $741M jump in current liabilities that nobody can explain yet:

Operating payables or customer deposits would flatter Q4 OCF and can reverse.
Capex payables would mean cash capex lags the accrual.
Current debt would be a refinancing item.

I don't know which it is. Until the 10-Q says, I wouldn't lean on "OCF direction improved."

My version of the test is OCF of about $225M or more and capex no higher than Q3's roughly $289M, a burn under about $65M. Failing that, I want clear evidence that capex intensity is falling.

2. Your two questions¶

Middle zone: what do I do? I stay out. The middle zone is "not repaired," and your framework says hold. Holding means you already own a starter bought before the information arrived. I'm not shorting, since the stock can rally on a guide even with weak cash. But nothing in the middle zone justifies initiating at 49–52x.

Gap fill before the print: still waiting? Yes, and the math argues for it. At about $257, the multiple on your annualized Q4 figure goes from 52x to about 57x with no new information. Your 215 stop would be 16% away, against 12–15% to the 288–295 cluster. Your own reward-to-risk ratio flips. A gap fill into the 10-EMA, with the daily SuperTrend overhead at 292, is also where a relief rally in a downtrend tends to stall. That last part is inference, not data. The cost of waiting is real: I'd miss about 9%. I'd rather pay that than carry the position through three binary events.

3. The trade frame overstates the protection¶

A closing stop doesn't survive a gap. Last November's print opened at 153.70 against a prior close of 134.63, a gap of 14%. Two ATRs below the close is 195.5, about 18% lower. Gaps cut both ways, so a print is roughly a coin flip with a stop that can't protect you. It isn't the 8–9% risk you sized for.
Events land before the test. The FOMC is Oct 28–29, and the hyperscaler prints and the month-end close follow. If October closes below 228.68, all three SuperTrend tiers are down and your starter is long against every one. You moved your line to 215 because 228.68 sat inside the noise. That's honest, but it also means the tool's regime reading goes fully bearish while you hold.
The "three tests of support" record isn't independent of regime. The two prior bounces happened with the weekly trend up and the 50-SMA above the 200-SMA. Neither is true now. You haven't answered that.

4. The "low bar" is lower only on favorable inputs¶

Your 2.5% sequential bar starts from the derived Q4 base, which you said may include timing. Q3 growing at its own 7.1% trend gives about $1.93B, and Q4 came in about $110M above that. From a $1.93B base, hitting +22.5% needs about 5% sequential growth per quarter. The bar doubles. The $1.93B base is my illustration, not a forecast.
The 41x end needs a 13% net margin. Only Q1 got there, and Q1 is the quarter you called unexplained. At Q4's 10.9% net margin and +22.5% growth, FY27 is about 49x.
Net margin hasn't tracked gross margin. The quarterly net margins are 14.3%, 8.7%, 10.6% and 10.9%. From Q3 to Q4, gross margin gained about 0.9 points and net margin gained 0.3. The leverage is visible from Q2 to Q3, but it isn't visible after that.
Your 52x takes the friendlier of two numbers. The feed shows net income of $770M against the filing's $787M. On $770M, derived Q4 net income is about $206M, which is about 57x annualized.
The operating-income-to-net-income gap compounds this. At 11.8% operating margin and roughly $170M of interest, pre-tax income is about $668M. That is $119M short of $787M even with zero tax. If that gap is non-recurring, core earnings could be around $670M or less, which is 70x or more. That is a sensitivity, not a finding. Interest, other income and the 11.8% TTM figure are all uncertain, and the 10-K bridge settles it.

Where this leaves us¶

I'm not saying the thesis is broken. I'm saying you're paying about 50x for a recovery in cash flow that the numbers don't yet show, and your plan buys before the test and relies on a stop that can't hold through the event. Waiting costs me some upside. Buying now costs you the option to choose after the evidence.

My question back: if the 10-Q shows the $741M is mostly operating payables or customer deposits, which flatter OCF and can reverse, does your top row still say "add" on an OCF of $225M? Bear Analyst: # Bear Closing Rebuttal: I'd Pay 60x for Proof, But Not 52x for a Promise

Bull, your revised test is much better than the first one. I'll take the improvement, answer your question directly, and then show why your own table leaves the starter sitting through the event whose most likely result is "don't add."

What I concede¶

Your revised table fixes my main objections. Stripping out payables and deposit stretch and measuring accrual capex is the right design. I accept your ~17% (~$350M) capex ceiling in place of Q3's $289M.
Revenue growth isn't my argument. Both of your bases need 2.5% or 5% sequential growth, below the reported 6.6% and 7.1%. My dispute is cash conversion and the multiple.
The 70x was a TTM sensitivity, and I'm retiring it. The operating-income-to-net-income bridge stays on the checklist because it can cut either way.
Capex is also an asset. Annualized Q4 gross profit of ~$3.15B against ~$2.05B in FY25 is a fair sign that earlier capacity paid off.
Waiting costs something. In the good state it costs the gap.

Your question: do I buy at $270 after a clean print?¶

Yes, a starter. That is the point: the premium over today's price buys the evidence. At $270 the market cap is about $53B. That is about 56x FY27 GAAP earnings at Q4's 10.9% net margin and about 47x at 13%. The proof would remove the cash risk, not the multiple risk, so I'd size for the multiple and add only after a second clean quarter.

Two things follow from that answer.

1. Your own rules say you wouldn't buy there. Your table says "Add" on a top-row print. Your bottom line says "no add above $257" and "trim into 252–262." At $270 you'd be trimming. Which rule governs?

2. The odds needed to beat waiting are demanding. Using your numbers, buying now beats waiting only if the print is good enough to gap to $270 (+14%) more often than it is bad enough to gap down 20%.

State	Buy now vs. wait
Good (gap to ~$270)	+13.8%
Middle	about 0, and nothing resolved
Bad (−20% gap)	−20%

Breakeven needs good outcomes to be about 1.45 times as likely as bad ones. The top row needs two strict conditions at once, while the bottom row needs only one of two. That favors waiting. The odds are my judgment, not data.

The top row fights your own thesis¶

In section 3 you argued that halving capex "means growth is ending." Your ceiling of ~$350M is 33–37% below Q4's $556M, which is the same argument at a smaller scale. Capex went from $129M a quarter to $289M to $556M, and you cite supply tightness through 2028 as the reason. If management keeps building, the top row is out of reach. If management cuts capex a third, you've told us what that means.

Working capital is the second problem. A business that grows revenue 13% sequentially normally consumes cash. OCF of $225M or more while growing requires inventory and receivable turns to improve, not just stop deteriorating. Your table doesn't test that, so I'd add inventory days and DSO flat or down.

By your own account the middle row is the most likely result, and the middle row says "hold, don't add." You'd be buying ahead of an event whose likeliest outcome gives you no new reason to own more.

Where I hold the line¶

1. The cash gap is mostly working capital. FY26 EBITDA was $1.42B and OCF was $80M, a $1.34B gap. Interest is my estimate of ~$170M, and cash taxes are unknown. By elimination the working-capital drain is roughly the size of the whole $1.1B capex program. By my arithmetic from the balance sheet, current assets ex-cash rose ~$2.7B and current liabilities rose ~$1.1B, a net build of ~$1.7B on $1.3B of added revenue. That assumes it is all operating. If it is, capex isn't the whole story.

2. Gross profit isn't earnings. Derived Q3→Q4 gross profit rose ~$108M, but net income rose ~$32M, about 30%. Your gross-profit-versus-capex check shows earlier capex paid. It says little about the $556M spent in Q4, which has barely begun producing, or about the depreciation that comes with it.

3. The plan trims into strength and stops out into weakness. The starter shrinks if the gap fills and is gone if 215 breaks. So the pre-print trade monetizes the TD-9 bounce, which we both called thin, and the fundamental test arrives after. At 2.5% sizing (0.5% maximum loss), I have no quarrel with the risk. But a 14% win on 2.5% of the portfolio is about 0.35%. That is a tactical trade, not the thesis.

4. Much of the evidence is already public. The fundamentals feed cites the annual filing for the $787M. The $741M current-liability jump, the inventory and receivables split, the capex-payables note and the operating-to-net-income bridge don't need the print. Reading that filing costs nothing, so I'd read it before sizing anything. If it shows the $741M is capex payables and the working capital is ordinary, I'd move closer to a starter. That is what would change my mind.

Where we stand¶

Sept-quarter result	Your action	My action
Clean OCF ≥ ~$225M, accrual capex ≤ ~$350M, turns flat or better	Add	Starter even near $270, add on a second clean quarter
Anything between	Hold, no add	Stay out
OCF < ~$70M, or accrual capex ≥ ~$500M with growth < ~5%	Exit	Avoid, with 170–210 as the next structure

Bottom line¶

We now agree on the business, the test and the exit. We disagree only on whether to buy before the test. The setup against buying is this: - The price is 52–57x run-rate. - The primary trend is down, and the monthly stop at 228.68 sits 3.7% away with seven sessions to the Oct 30 month-end close. - The FOMC on Oct 28–29 prices 97% odds of no 2026 cuts and 80% odds of another hike by Dec 10 on a thin market. - The print will likely gap in either direction, as it did last November.

The bull case is a good business with an unproven cash cycle. I'd read the filing now and buy the proof when it arrives, even at a higher price. I would not buy the promise today. Bear Analyst: # Bear Final: We Agree on the Business, and the Disagreement Is Worth About 40 Basis Points

Bull, your revised plan fixes most of what I objected to. The multiple gate, turns in the top row and a filing read before any buying are all improvements. I'll take the hits first, then say why I still wouldn't buy before the print.

What I concede¶

My breakeven mixed cases. I paired your +14% good gap with a −20% sizing gap. With a symmetric ±14%, breakeven is 1:1, not 1.45x.
Table rows aren't price outcomes. The stock can rally on a guide despite weak cash, or fall on clean OCF with a soft guide. The table governs adds and exits, not the direction of the gap.
Growth doesn't mechanically consume cash at COHR. FY25 grew 23.4% and produced $634M of OCF. That is your best evidence the top row is reachable. Two offsets: FY25 capex was 7.6% of revenue versus 15.5% in FY26, and FY25 growth partly rebuilt a base that had fallen 8.8%. The second is my inference.
The capex ceiling is an intensity test, not a halt. I overreached in calling $357–391M the same argument as halving. Whether management keeps building at Q4's pace is a judgment call, and your plan handles it.
A multiple gate beats a price gate. I also have no quarrel with a 2.5% position sized to a 20% gap.

Where I hold the line¶

1. With a symmetric gap, the starter has no edge from the print. That is what 1:1 means. Two reasons remain for owning it before the print: "30% cheaper" and a bounce setup we both called thin.

2. "30% cheaper" is anchored to the peak. I'm holding the share count constant and using derived Q4 net income annualized at $892M. On that base: - The $338 close on Oct 6 was about 75x. - Today's price is about 52x. - Your 215 exit is still about 47x.

Falling from 75x to 52x doesn't make 52x cheap. The stop is a chart level, not a valuation floor.

"Unchanged published numbers" cuts both ways. The market had those numbers at $338 too. What changed was the price it will pay for them, and that is driven by rates (97% odds of no 2026 cuts) and AI-capex doubts. Neither is in the 10-K.

3. A clean 10-K doesn't test the open question. The filing is public, covers through June 30, and was available during the entire selloff. - It can rule out a failure mode, such as aging receivables or a payables stretch. - It can't tell you September-quarter OCF, the first quarter that carries Q4's capex run rate. - A pass moves you from "no starter" to "starter" without new information on the one thing we agreed matters. - Because Q4 is derived, decomposing the $741M needs the March 10-Q balance sheet next to the 10-K.

4. Your reconciliation is half right. I'll accept that the $1.7B balance-sheet build is an upper bound. But the cash-flow arithmetic puts the floor above $1.1B: - Net income of $787M plus D&A of about $580M (the feed's $1.42B EBITDA less about $840M of operating income) is about $1.37B before working capital. - OCF was $80M, so roughly $1.3B was absorbed, before adding back stock comp and other non-cash items. - That makes the range about $1.3–1.7B, not $1.1–1.7B.

Either end exceeds the entire $1.1B capex program. That is why the composition of the build matters more than the capex itself.

5. Passing the top row still burns cash. At $225M of OCF and capex at your $357–391M ceiling, FCF is about −$130M to −$165M a quarter. That is far better than −$486M, and I'd call it repaired enough for a starter. It isn't self-funding, though. Any funding comes through dilution or interest expense, and both come out of the per-share earnings the 57x is applied to.

6. The size of the disagreement is the best argument. By your own math, +14% on 2.5% is +0.35% of the portfolio and −20% is −0.5%. We're arguing over about ±0.4% of portfolio. At that size the starter can't be the thesis, so it is only a bet on the gap, and I'd rather make that bet with information.

What I'd do instead¶

Read the 10-K and the March 10-Q now. It's free and I agree it comes first. If the $741M is mostly capex payables and the working-capital build is ordinary, I move from "no" to "small, at a better level or after the print."
Take the bounce at the level. A retest of 215–222 with volume expanding on up days cuts the stop distance from about 9% to roughly 3–5%. It also gets me the confirmation the technical report said it needs, which today's partial 3.05M-volume bar can't provide. The cost is that I may miss the gap fill, and I accept that.
Buy the proof after the print. A clean September-quarter cash-flow statement, with turns flat or better and accrual capex at or below about 17% of revenue, earns a starter even at 56x. A second clean quarter earns the add.

Bottom line¶

Bear stance: wait. We agree on the business and the test. Revenue is accelerating in the reported quarters, margins are expanding, and solvency isn't in question. What remains is a roughly 52–57x stock in a downtrend, with a funded-by-capital-markets cash cycle that is unproven, and your starter would sit through the FOMC (Oct 28–29), the Oct 30 month-end close, hyperscaler prints and COHR's own gap. The last November print opened 14% higher, and nothing says the next one must.

You'd pay about 50x for a small option, and I'd pay up to 60x for proof. The risks the filing read can't remove are rate-sensitive multiple compression, the unverified cash cycle and event gaps. I'd rather take them after the evidence than before it. Bear Analyst: # Bear Close: Your Plan Now Matches Mine, Except for Half a Position Bought Before the Gate

Bull, this is a good place to stop. We agree on the business: reported growth is accelerating, margins are widening and solvency isn't in question. We agree on the test (cash conversion ex-stretch, on accrual capex) and on the exit (a close below 215). We now also agree on the retest entry. What's left is a 1.25% first half bought before the month-end close. By your numbers that is worth +0.18% if the print gaps up 14% and −0.25% if it gaps down 20%.

What I concede¶

Your hurdle table is right. $66.6B and $46.7B over $950M and $1,134M give 70x/59x at $338 and 49x/41x at $237. The required growth is lower than it was 11 sessions ago, and I've never argued that growth is the problem.
The filing read moves the odds more than I said. I called it a test that can't touch the open question, which overstated it. If the build is inventory, a snap-back is plausible. If it's receivables or a payables stretch, it isn't. The filing shifts those odds without settling them.
Top-row funding is benign. About $600M of annual burn takes net debt to roughly 2.0x EBITDA, with about $33M of extra interest. That's a drag, not a solvency issue.
Your retest trigger and the 1.25% sizing are reasonable. The retest was my idea, and I won't argue against it.

Where I hold the line¶

1. Your funding math uses the best row. You called the middle row the most likely outcome. If capex stays near Q4's $556M and OCF lands at $70–225M, the burn is $331–486M a quarter, or about $1.3–1.9B a year. That takes net debt from $2.3B to $3.6–4.2B, about 2.5–3.0x trailing EBITDA. Interest at your 5.5% is then roughly $70–105M pre-tax, about 8–12% of annualized NI instead of 4%. Cash of $1.16B covers only about 2.4–3.5 quarters of that burn before new financing.

Trailing EBITDA understates the run-rate, and neither of us has revolver or covenant data, so treat the ratios as illustrations. If any of the funding comes from equity at a lower price, the flat share count in your FY27 table also breaks.

2. The hurdle table shows cheaper, not cheap. It holds earnings fixed and moves the price, so it can only say a lower price is lower. Whether 49x is a fair multiple is the open question. - The 41x end needs a 13% net margin, which only Q1 produced. - From Q3 to Q4, gross margin gained about 0.9 points and net margin gained 0.3. - $1.1B of capex carries its depreciation into FY27. - Nothing in our data resolves the two causes of the de-rating, higher-for-longer rates and AI-capex doubts. AI-bubble odds are up 3.1 points on the week.

3. Your gate sits after the purchase. Your rule is "no adds if October closes below 228.68," but the first half is an add made before that is known. If the close lands below the line, you hold a starter against all three SuperTrend tiers, under a rule that stops you adding but doesn't stop you holding.

The window before then has three events, and two of them speak to why the stock fell: - Hyperscaler capex commentary. The selloff was attributed to AI-investment worries, and this is the direct read on that. The news report lists Meta among prints in focus. I have no confirmed dates for the others. - FOMC, Oct 28–29. Polymarket has 86% on a hold and 12% on a hike. - The Oct 30 month-end close, seven sessions away.

By your own symmetric-gap logic, waiting for these costs no expected value. It only lowers variance, which you called legitimate. The price is the gap fill: 9% on 1.25% is about 0.11% of the portfolio.

4. The supply-crunch leg is thinner than your bottom line implies. The only evidence is a TrendForce headline, relayed on StockTwits, about AI fiber, with COHR listed as "in focus" beside GLW and VZ. We have no pricing, backlog or lead-time data for COHR's own products. A shortage that justifies a capex race is also one every competitor is answering, but that's inference. The CPO adoption debate flagged in the news report bears on what the new capacity is for. It's headline-only, so I can't size it.

Where we stand¶

Step	Bull	Bear
Read the 10-K and 10-Q (the $741M, inventory/receivables, capex payables, operating-to-net-income bridge)	Required	Required
Oct 30 close vs 228.68	Gate on adds	Gate on the first buy
First ~1.25%	After the filing, before the print	After the filing and a close ≥ 228.68, or on a 215–222 retest that holds on expanding up-day volume
Remaining ~1.25%	Retest hold, or clean print	Clean print only
Exit	Close < 215. OCF < ~$70M, or accrual capex ≥ ~$500M with growth < ~5%	Same

Your plan is mine with the gate moved ahead of the purchase and my second half reserved for the print.

Bottom line¶

Bear stance: wait, but briefly. Read the filing now. Let the FOMC, the hyperscaler commentary and the Oct 30 close resolve. Then take a starter if the regime line holds or the 215–222 zone retests and holds. Earn the rest from the September-quarter cash-flow statement.

Neither of us should pretend the first-half dispute matters much. It is worth 0.1–0.25% of the portfolio. What matters is where September OCF lands against $70M and $225M, and whether accrual capex falls toward 17% of revenue. If OCF comes in near $70M on $556M of capex, you've said the thesis broke at the cash line, and I agree. At 52–57x run-rate, nothing would be left underneath the stock but the multiple.

Research Manager¶

Recommendation: Hold

Rationale: This debate converged more than most. Both sides now agree on the business, the key test and the exit. What they still disagree on is timing, and on timing the bear had the better case.

The bull won the argument about the business. Revenue grew from $4.71B to $5.81B to $7.12B. Gross margin rose from 30.9% to 37.5%. Net income swung from -$159M to +$787M. Reported YoY growth accelerated from 17.3% to 17.5% to 20.6% without needing the derived Q4. Solvency is not in question: the current ratio is 2.43, D/E is 0.32x and net debt is about 1.6x EBITDA. The bear conceded all of this.

The bear won the argument about the price and the cash. FY26 operating cash flow was $80M against $787M of net income and $1.1B of capex. Working capital absorbed roughly $1.3-1.7B, which is more than the entire capex program. Derived Q4 free cash flow worsened to about -$486M.

Several items are still unexplained: - A $741M jump in current liabilities. - A gap between operating income and the $787M of net income. - A $787M vs $770M discrepancy in reported net income.

The stock trades at about 52-57x annualized run-rate earnings. The primary trend is down: the weekly SuperTrend is down and the 50-day SMA is below the 200-day. The monthly SuperTrend stop at 228.68 is only 3.7% away, with the Oct 30 month-end close, the Oct 28-29 FOMC (97% odds of no 2026 cuts) and hyperscaler capex commentary all landing before the print. The supply-crunch support is a single relayed TrendForce headline about fiber, not COHR's own pricing or backlog data.

The decisive point came from the bull's own concession. With a symmetric gap of about ±14%, the print offers no edge. Buying before it only adds variance, and the bull's "no adds below 228.68" gate sits after the purchase rather than before it.

The bear's case is not strong enough to justify trimming either. The business is accelerating, the stock has already de-rated from about 75x to about 52x, and both sides would buy on proof. The one variable that matters, September-quarter cash conversion, is unknown and arrives within weeks. That makes this a genuine Hold: keep what you have, don't pay up ahead of the evidence, and use a pre-committed staged entry so we can move up or down quickly once the data lands.

Missing from our evidence: - The confirmed earnings date. - Revolver and covenant data. - The operating-income-to-net-income bridge. - The composition of the working-capital build. - Confirmed hyperscaler print dates.

Strategic Actions: 1. Now through about Oct 28: read the FY26 10-K alongside the March 10-Q. Check four items: (a) The composition of the $741M increase in current liabilities: operating payables or customer deposits, capex payables, or current debt. (b) The inventory vs receivables split and its aging. © Capex sitting in payables. (d) The bridge from operating income to $787M of net income, including any non-recurring items and why the feed shows $770M. If the $741M is mostly operating payables or deposits, or receivables look concentrated or aging, take no new position. Existing holders above a starter weight should trim toward about 1.25% of the portfolio.

No new buying before the FOMC (Oct 28-29), the hyperscaler capex commentary, and the Oct 30 month-end close.
First tranche: about 1.25% of the portfolio, roughly a quarter of a standard full allocation. Buy it only if the filing check passes and one of these holds:
October closes at or above 228.68.
A retest of 215-222 holds with volume expanding on up days. Size it so a 20% earnings gap costs at most about 0.25% of the portfolio.
Second tranche: another 1.25%, bringing the pre-proof starter to about 2.5%. Add it only after a clean September-quarter print, which means all of the following:
OCF of at least about $225M, excluding any payables or deposit stretch.
Accrual capex at or below about 17% of revenue (about $350-390M).
Inventory days and DSO flat or better.
A valuation at or below about 57x annualized quarterly GAAP net income. At $270, that requires about $233M of quarterly net income. Go to a full standard allocation only after a second consecutive clean quarter.
Existing holders: keep current exposure but do not add before the print. Trim into strength at the 252-262 gap fill and 10-EMA, or at the 288-295 resistance cluster. If October closes below 228.68, make no adds and cut any oversized position back to starter size.
Exits:
A daily close below 215. Expect gap risk toward about $195, with 170-210 as the next support structure.
A September print with OCF below about $70M.
Accrual capex at or above about $500M with sequential revenue growth below about 5%.
Re-rating triggers: a clean print plus a clean filing moves us to Overweight. An impaired cash print, or a filing showing a payables or deposit-driven OCF stretch, moves us to Underweight or Sell.

III. Trading Team Plan¶

Trader¶

Action: Hold

Reasoning: The business case is strong: revenue, gross margin and net income are all accelerating, and solvency is fine. The price and cash case is weak: FY26 operating cash flow was only $80M against $787M of net income, working capital is unexplained, and the stock trades at about 52-57x run-rate earnings. Technically the primary trend is down (weekly and daily SuperTrend down, 50-SMA below 200-SMA), and the monthly SuperTrend stop at 228.68 is only about $8.69 below the 237.37 close. The daily TD-9 and the narrowing MACD histogram suggest a bounce, but nothing confirms a reversal. With a roughly symmetric earnings gap, buying before the September-quarter cash print adds variance without edge, and the case isn't weak enough to justify trimming either, so keep exposure and wait for the October month-end close, FOMC, hyperscaler capex commentary and the print.

Entry Price: 228.68

Stop Loss: 215.0

Position Sizing: Portfolio holdings are unknown, so this is guidance to apply to your own book. Existing holders: keep current exposure, add nothing before the print, and trim into strength at the 252-262 gap and 10-EMA or the 288-295 cluster. If the filing check fails or October closes below 228.68, cut any oversized position back to about 1.25% of the portfolio. New money: no buying before the Oct 30 month-end close. A first tranche of about 1.25% of the portfolio is allowed only if the 10-K check passes and October closes at or above 228.68 (the entry reference), or a retest of 215-222 holds on expanding up-day volume. A second 1.25% (about 2.5% total) is added only after a clean September-quarter print. Exit on a daily close below 215, keeping in mind gap risk toward about 195 with an ATR near 8.8% of price. Size so a 20% earnings gap costs at most about 0.25% of the portfolio.

FINAL TRANSACTION PROPOSAL: HOLD

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: I'll open the debate, since neither of you has spoken yet. I'll answer the arguments I expect, because they're predictable.

The aggressive case for Hold on COHR is that Hold keeps you in the game at the point where the alternatives are worst. Selling or trimming means exiting after a 29.8% drop in 11 sessions, with the stock sitting on a 215-222 floor that has been tested three times, and with the monthly SuperTrend regime still up. Buying aggressively means paying up before a cash-flow print that could confirm or break the bear case. Hold with a pre-built scale-up plan avoids both mistakes. COHR is still up about 96% from 120.79 a year ago, and I want to keep that exposure.

The conservative analyst will lead with cash conversion, and I'll give them that one. FY26 operating cash flow was $80M against $787M of net income, and free cash flow was roughly negative $1B. That's the real weakness, and it's why the plan adds nothing before the print. But look at what capex did. It went from 7.6% to 15.5% of revenue while revenue growth accelerated to roughly 34% in the derived June quarter and gross margin hit about 38.5%. TrendForce sees an AI fiber supply crunch through 2028. A company spending $1.1B on capacity into a shortage looks different from one burning cash on a dying business. The balance sheet funded it, with a 2.43 current ratio, debt-to-equity of 0.32x and $1.16B in cash. The honest risk is that the working-capital build is inventory that gets written down if AI spending digests, and I can't resolve that from these tools. That's why the 10-K check gates the first tranche. I'd gate it, not run from it.

On valuation, 52-57x run-rate earnings is rich, no argument. But earnings went from negative $0.52 per share to $4.12 in a year, and the stock has been range-bound between roughly 215 and 440 for six months while earnings kept compounding. The denominator is growing into the price. I won't lean on the 17x forward P/E, because it's probably on an adjusted basis.

The technical bears have the trend right. The weekly and daily SuperTrends are down, the 50-SMA is below the 200-SMA, ADX is 35, and OBV confirms the selloff. But if you wait for trend confirmation, the weekly SuperTrend flips at 395.74, which is 67% above here. Insisting on that confirmation means buying after the money has been made. The plan doesn't wait for it. It asks for something achievable: an October month-end close at or above 228.68, or a 215-222 retest that holds on expanding up-day volume.

Insider selling is the point I'd dismiss fastest. About $42M of sales since late October 2025 is roughly 0.09% of a $46.7B market cap. The CFO sells roughly monthly, which looks like a plan. Bain's remaining stake is a real overhang, but at about $1.8B it's under 4% of market cap. I'd rather see insider buying, but its absence isn't a thesis break.

Macro is the same story. The October FOMC is priced at 86% hold, with the hike probability down about 20 points on the week, recession odds are 8%, and an AI bubble burst in 2026 is 9%. That tail is rising, and I respect it, but it's small, and the stock has already fallen 44% from its closing high.

To the neutral analyst, who will probably say wait, I'd say waiting isn't free, and the plan knows it. The risk-reward is decent. From the 228.68 entry reference with a 215 stop, you risk about 6% to target 252-262, a gain of 10-15%, and the 288-295 cluster is 26-29% above. That's roughly 1.7 to 2.4 times your risk to the first target and over 4 times to the cluster. The 215 stop also isn't an arbitrary one-ATR stop that noise will clip. It sits under three dated lows and the 215.09 lower Bollinger band, so it's structural.

I'd also push back on the idea that the earnings gap is a coin flip you must avoid. Optics peers are rallying into their prints, and Susquehanna's $350 target, even after the cut, is about 47% above the current price. I'm not claiming an edge. I'm saying the skew isn't obviously negative, and the sizing makes that question affordable. A 20% gap costs 0.25% of the portfolio, and a second tranche only comes after a clean print. That is a bold structure that pays when the thesis works and survives when it doesn't.

Here's where I'm less cautious than the plan. Existing holders should trim only a slice at the 252-262 gap and keep a core for the 288-295 cluster, because a stock that bounced to 347 and 379 after the last two tests of this floor can run again. That is two episodes, not a law, and I won't pretend otherwise.

I'm also not leaning on the retail posts. The labeled StockTwits split of 9 bullish to 0 bearish is thin, repeated and partly unverified, and the Nvidia investment claim is unconfirmed. Leveraged call buying at these levels is a reason for humility, not a signal. The case stands on the accelerating revenue, expanding margins and the structural floor, with the cash-flow question gated and sized.

My position is Hold, keep exposure, add on confirmation, and respect the 215 stop. Aggressive Analyst: Let me start with what you've earned, because the plan I opened with has real errors.

Conservative, your arithmetic is right. From 237.37, the 215 stop is 9.4% away and the 252-262 gap is 6 to 10% up. That's roughly 0.66 to 1.1 times risk, not 1.7 to 2.4. The "over 4 times" to the 288-295 cluster is really 2.3 to 2.6 from here, because I ran the numbers off a 228.68 entry nobody can transact at. Neutral's point is sharper still: the stronger the October close, the worse the entry, so the month-end close is a bad buy trigger and I'm dropping it. I'm also dropping "still up 96% on the year" as a reason to hold. It's an anchor, and the right test is whether you'd own this size today. And 215 is the one-ATR line, with 217.83 printed yesterday, so it isn't structural protection. It's a line where I act on a daily close, and size is the real defense.

Here is where I think the conclusions still don't follow.

Start with the lower highs (440, 439.68, 391, 342). They argue for where to take profits, not for being out at the floor. If the next rally fails at the 288-295 cluster, well below the October 5 high of 341.76, it still pays 21 to 24% against a 9.4% risk to the stop. You don't need new highs for this to work. You need a rally that tops lower than the last one.

Selling now is also the worst place to cut. The stock is down 29.8% in 11 sessions and sits in the bottom 15% of its Bollinger range. It opened above the prior close and finished up 2.4%, with a gap 6 to 10% overhead. Conservative, you're right that the z-scores aren't at minus 2 and RSI shows no divergence, so I'm not calling this oversold. But limit orders in the gap beat a market sale at the lows, and Neutral's ladder does that. Meanwhile October hike odds fell about 20 points on the week to 12%, with 86% priced for a hold. The Fed risk you're asking holders to flee is receding.

On the trigger being a coin flip, sure, the stock could close either side of 228.68. But it's the monthly regime line, a close below it puts all three SuperTrend tiers down, and it prints October 30. That's after the FOMC and the hyperscaler capex commentary and before COHR's own print. You see the macro resolve and cut before the cash-flow number lands. I'll concede Neutral's point that someone well above the size band shouldn't wait that long.

On the fundamentals, you've both landed real hits, and I'll give ground. Non-cash current assets rose 91%. Even annualizing the derived June quarter, revenue is only about 41% above FY25, so the build outpaces growth and isn't just a growth-rate artifact. Gross profit rose about $208M from the September quarter to the derived June quarter, while net income was flat at $226M and $223M. I can't explain that gap from these tools, so I'm retiring "earnings compounding." The print has to show the margin reaching the bottom line.

I'd still push back on the runway. Neutral is right that cash fell $430M, not $486M. Debt-to-equity is 0.32x, net debt is about 1.6x EBITDA, and there's market access at a $46.7B cap. A $2B raise would be about 4% dilution. That's painful but survivable, and it's why I'd watch the capex guide, not run. Derived operating cash flow also went from about negative $94M in March to about positive $70M in June while capex doubled. That's one derived data point, but the direction is recovery. Neutral's refinement is the right gate: inventory and receivables growth against revenue, plus the capex guide, not a single quarter's operating cash flow. The 10-K check is free, so do it today.

On insiders, Bain's remaining 7.75M shares is about one session of recent volume of 6 to 10M. That's an overhang you can digest. The seven sales totaling $8.2M came at $268 to $324, and there are no filings in the past week of this drop, so nobody is dumping into it. The lack of buying is real, but it's not a thesis break.

I'm also dropping Susquehanna's $350. Targets follow price down. And I'll flag that the 9% AI-bubble odds sit in a $2.5M market. Neutral noted that those odds barely moved while the stock fell 30%. That tells me the selloff looks more like positioning in a 2.11-beta stock than new information, and positioning can unwind too. That's an argument, not evidence, but it cuts both ways.

On sizing, I'll take Neutral's band: at or under about 2% of the portfolio, hold through the print. A 30% gap on 2% costs 0.6%, and 30% is the gap I'd stress against after this tape. But Neutral, you called 1.25% a bucket cap across AI optics and then said to hold if COHR alone is under 2%. Those two don't fit together, so pick one. I'd pick 2% for COHR and look at the basket separately. Above 2%, I accept limit orders in the gap and a sell-half backstop on October 28. I'd rather the pre-committed response to a daily close below 215 be a halving than a full exit. Below 215 there's thin structure down to the 170-210 range, so that's the honest risk.

For new money, Neutral's retest-only trigger on 215-222 with expanding up-day volume is better than mine. But I'd keep the first tranche near 1.25%, because a 30% gap on that costs about 0.375% of the book, and a 0.6% starter is too small to matter if the thesis works. Conservative, your 292.15 re-entry is the "buy after the money is made" problem. It's 23% above the price, at the bottom of the resistance cluster, and the weekly flip is 67% higher at 395.74. And zero for new money while existing holders keep 1.25% fails your own test. Either the position is acceptable or it isn't.

So I'm staying with Hold. I'll keep the exposure inside a size band, add only on a verified retest after the 10-K check, sell into the gap, and honor a daily close below 215 as a halving. The cash-flow question is real, but a 0.4 to 0.6% book hit is what we pay for a seat at a floor that has held three times, into a print that could confirm the thesis. Aggressive Analyst: Let me bank the concessions first, because they're real. I'll take Neutral's two-number structure, COHR alone plus a basket cap. The sentiment data shows COHR trading with LITE, AAOI, GLW and MRVL, so Conservative is right that a holder with other optics names carries more of this risk than the COHR line shows. I'm dropping both thin Polymarket contracts, the 9% bubble and the 8% recession. And for anyone above the ceiling, the decision date is the October 28 close. October 30 is a Friday, so a month-end rule can't act until Monday.

Now size, where I think Conservative's 1% is the number that doesn't hold up. It comes from dividing a 0.25% loss budget by a 30% gap. But 30% in one session is about three and a half ATRs, and more than double the only earnings gap anyone has cited, the 14% on November 6 last year. Yes, that gap launched from 135, and yes, volatility is higher now, which is why I'm stressing at 30 and not 14. But if you size for a tail twice as big as anything observed, you're underexposed in every other outcome. At Neutral's 1.5%, the observed 14% gap costs about 0.2%, inside the trader's own budget, and the doubled stress case costs 0.45%. I'm moving down from 2% to 1.5% and no further.

On the gap math, Conservative says a gap to 195 makes the 288-295 payoff only 1.2 to 1.4 times the loss. Those are two different branches, though. The loss happens in the world where the print is bad and the gain in the world where it's good, so the ratio only means something with a probability attached. At 1.2 times you break even winning about 45% of the time, and at 1.36 about 42%. Everyone here keeps calling the print a coin flip, and a coin flip clears that bar. The good branch doesn't always travel all the way to the cluster, so it isn't free money, which is why I accept the size cap. On noise clipping the stop, the plan's trigger is a daily close under 215, not an intraday touch. All three tests held on a close, at 219.65, 222.05 and 231.80. Yesterday printed 217.83 and closed almost 14 points higher. A close-based line isn't the same thing as a line one ATR below price.

On cash flow, Conservative is right that a $70M quarter is under half of last year's quarterly average on a bigger revenue base. Neutral is right that the number can't tell healthy working-capital growth from a stuffed warehouse, which is why the 10-K check comes first. I'd push back on "flat earnings," though. That compares the September quarter with the derived June quarter. The last three quarters are 147, 191 and 223, up about half from the trough. The September figure is the outlier I can't explain, so I'm not reviving "compounding," but endpoints are a selection too. On dilution, I'll grant the window can close. Even so, a $2B raise is about 4% of the company at today's cap and about 6% if the stock is another 30% lower. That's a haircut, not a thesis break.

On rates, I'd keep the deep contracts, since they're the only well-traded macro data we have. The October hike contract carries $12M, and it fell about 20 points this week while the stock fell 30%. So this drop isn't a rates story. The no-cuts regime is a standing condition, not something that arrived in October. What moved was AI-capex worry and positioning, and a sentiment shock can reverse faster than a rate regime. I can't prove that, so treat it as argument.

Conservative says there's been no flush, with RSI never at 30 and z-scores around minus 1.5. True, and I'm not calling it oversold. But the tape did something else. It printed three closes within about a dollar of each other, at 232.90, 232.02 and 231.80, with volume fading from 9.95M to 6.15M, then a gap-up open. Sellers stopped pressing without a capitulation, and a stall is a fine place to rest limit orders in the gap. A 30% drop also resets the bar for the print, so a result that disappointed at 340 may be merely fine at 237. That too is an argument, not evidence.

I'll concede Bain on mechanism. It would be a block, and the window plausibly reopens after the print. But a $1.8B block is under 4% of the market cap and one session of discount, and when it clears, the overhang clears with it. It's also one more reason to ladder sells into 252-262 before the print and not after.

On the month-end trigger, oversized holders now act on the 28^th. For holders inside the ceiling, I'd make an October close under 228.68 a review, not a mechanical sale. They've already paid for the uncertainty through size, and a close a dollar under the line carries the same information as one a dollar over it. The 215 close is the line with an actual floor behind it.

For new money, I'll take Neutral's 0.75%, which fits the 0.25% budget at a 30% gap, and I'll stop arguing about 1.25%. Conservative, though, you said 292 is a bad place to buy and then said you're fine paying it after a clean print. Pick one. A clean print probably puts the stock at 270 to 292, which is 23 to 33% above a 220 retest. That is the price of certainty, and I'm willing to pay it for the second half. But it makes the retest the only cheap exposure on the board, so the 10-K check should happen today and the starter should be real. The starter also doesn't have to ride through the print. If the retest holds and the gap fills at 252-262, that first piece can do its job before the number lands.

So I'm staying with Hold, with numbers. The ceiling is 1.5% for COHR and about 3% for the optics basket, with limit orders in the gap and the 28^th as the deadline for anyone over. A daily close under 215 halves the position, and new money starts at 0.75% on a verified retest after a clean 10-K. Confirm the earnings date today too, since no tool returned it. A 30% gap costs about 0.45% of the book. The upside is owning a name 44% off its high into a print where the bar just got reset. Aggressive Analyst: Three analysts who started far apart now agree on most of the plan. Nobody wants a holder sold to zero, nobody adds at market before the print, limit orders go in the 252-262 gap, a daily close under 215 means halving, and new money waits for the free 10-K read and a closed-bar retest. What's left is 1.25% versus 1.5%, which on a 30% gap is about 0.075% of the book. That's smaller than the error in any input we've used, so I'll concede what I should and defend the little that's left.

On concessions, Neutral is right about the Fed date. The report says the 28^th to 29^th, but the contract resolves on the 29^th, and if the statement lands on the 28^th, that day's close already contains the news. I'll take the 27^th close as the deadline for anyone over the ceiling, since it's before the statement under either calendar.

Neutral's breakeven correction also holds. I paired a 21-24% win with an 18% loss. The upside I can underwrite on the print is the 14% gap, about 271 from here. Against an 18% gap down, that needs the good branch to hit roughly 56% of the time, so the print isn't a free option.

Conservative is right that the closes that held were 219.65, 222.05 and 231.80, so the closing floor is nearer 220 than 215. That strengthens the rule. A close under 215 is below every closing low in the range and below the 215.09 lower band, so it's a real break. I'll also accept Neutral's default that a weak October close steps a holder inside the ceiling down to 1% on Monday. It's a quarter-point step, pre-committed, which is what I wanted.

On size, I'll sign Neutral's version: 1.25% until someone reads the filing, 1.5% if it's clean, 1% if it's flagged. Conservative, you said the ceiling can rise in an afternoon but a gap can't be undone, and that's why I accept 1.25% until it's read. But I'd push back on stopping at 1.25% after a clean filing. My 30% stress gap is mostly the bad version of the cash story: inventory written down, a raise into weakness. A clean filing takes the worst version off the table, so the stress gap should come down to maybe 25%. At 1.5%, that costs 0.375%, the same as 1.25% at 30%. I'll own that this is a 0.375% budget, above the trader's 0.25%. But the gap assumption moved because we learned something, not because I picked the size first.

Conservative's line that weak cash can't support the bull case is true, but the bull case doesn't rest on cash. It rests on derived 34% revenue growth, 38.5% gross margin and a fiber shortage seen through 2028. Cash is what could break it, and it's gated. The stock is also 44% off its high with that question already open, so the price isn't ignoring it. We agree 57.6x isn't cheap. The question is whether the sized position has a positive payoff given what's already priced, and the sizing means I don't have to be very right.

You've both treated the Fed and the hyperscalers as hazards ahead of the print, but they're also information. Meta is in focus this week, and the other hyperscalers report before COHR on any reasonable calendar. As Conservative said, this drop wasn't a rates story. It was an AI-capex digestion scare, and capex guides from the companies writing the checks speak directly to that fear. They arrive while a holder can still act with limit orders working, so this isn't holding blind through an event.

The ladder also shrinks what rides into the print. If a relief rally fills the gap first, the excess is gone and only the core carries the number. A 14% good-print gap to about 271 would run through those same limits too. I'm not asking the print to pay 21-24% on the whole position, only for the core to survive and the trimmed slice to fill.

For new money, I'm at 0.75% after a clean filing on a closed-bar retest of 215-222. Conservative is right that confirmation may arrive above the low and shrink the reward-to-risk. In that case you don't buy. New money isn't forced to take the setup, and a miss costs only the opportunity. The second half comes after the print on inventory, receivables and the capex guide, and I'll pay 270-290 for that answer.

So I'm staying with Hold, and it isn't inertia. The ceiling is 1.25% now, then 1.5% or 1% after the filing. The basket is sized by what it loses, limits sit in the gap, anything over the ceiling is cut by the 27^th close, a weak month-end steps down, and a close under 215 halves. The aggressive part isn't a bigger number. It's declining to sell a name 44% off its high, with accelerating revenue and margins, at a floor that has held three times, when the cheapest exit is a limit order 6 to 10% higher. Keep the seat, size it so a bad answer costs under half a percent, and let the print tell you whether to pay up. Aggressive Analyst: I'll take Conservative's trade on the filing, because Neutral's evidence closes it. The June balance sheet was public through the whole slide. Insiders were selling into it at 268 to 324 in late August and September, the stock was still 337 on October 2, and then it lost 30% in eleven sessions. A document the market had for six weeks can't be what moved the price, and it can't tell us what the September quarter looks like. So the filing is a veto, not a license. If it's flagged, the ceiling drops to 1% and there's no new money. If it's clean, nothing changes for holders and the 0.75% starter is permitted. Only the print lifts the ceiling. That costs me the quarter-point I was arguing for, and the 25% stress-gap case I made for it rested on a read that tells us nothing new.

On the ladder, Conservative is right that it's the upside and the 27^th close is the protection. Whatever hasn't filled by then goes at market, and that's the price of a shot at 6 to 10% more. The first rung at 252 is about $15 above the close, less than one ATR of $21, so I think a fill is likelier than not. I haven't computed that, and it only helps in the rally branch.

I'd push back on the ratchet, though. The COHR position never moved. It's the trader's 1.25% from the start. What changed is the label on what it costs: 0.25% at a 20% gap, 0.375% at 30%, which is the stress we all agreed was more honest. The 0.45% was my 1.5%, which I've withdrawn. The 0.75% for the sleeve isn't an add-on to COHR. It's the cost of the other optics names, and Neutral has the right method: pick the group loss the book can take, derive the weights, and cut the other names before COHR. I'll also accept that "under half a percent" is a central estimate. A 40% fall from here would put COHR near 142, close to where Bain sold last November, and that costs 0.5% on 1.25%. I'd rather say that than defend a cap that doesn't exist. And "44% off the high" is a path, not a price, so I'm retiring it along with the 96%.

Conservative, your answer to "would you buy this size today" is 1.25%. That is the trader's number, so the case for selling is gone and the three of us are describing the same Hold. The "no edge, so smaller" argument is fair, but Neutral's reply holds: selling to zero is a bet on a bad answer too. I'm not claiming an edge on the print. The 1.25% is the cost of keeping a seat in a business whose derived revenue growth is about 34% and gross margin about 38.5%, while the cash-conversion question gets answered. I can size that cost, and the 27^th, the step-down and the 215 halving limit it.

I still lean forward in three places.

Don't sell at market into this tape. The daily TD-9 is complete, the MACD histogram has narrowed for the first time, and the close sits at about 15% of the band width, with a gap 6 to 10% above. A limit order is a better exit than a market order.
Make the retest starter real. At 0.75% on a closed-bar hold of 215-222 after a clean filing, it's half the ceiling. If the retest never comes, we don't buy, and the filing check and the closed-bar rule shouldn't become reasons to never act.
Pay up after the print. Neutral says 2% needs a reason beyond the print. I'd say the print is the reason, because cash conversion is the one thing capping the size. If inventory and receivables grow slower than revenue, the capex guide is funded and operating cash flow is turning, I'd go to 2% and treat the trader's 2.5% as a ceiling, not a target. Valuation at 57.6x GAAP and about 34x EV/EBITDA, a beta of 2.11 and AI-capex digestion all remain, and no print resolves them. Paying 270 to 290 for that answer is the price of certainty, and it's a better use of risk than leaning in blind at 237.

On dates, I'm taking the 27^th close as the deadline for any excess, and I'd make the step-down the earlier of the Monday after month-end and the last close before the print. Verify the FOMC day and COHR's earnings date today, since no tool returned the latter.

I'm staying with Hold. That means a 1.25% ceiling going in, 1% if the filing is flagged, limits in the 252-262 gap now, and any excess gone by the 27^th close. A weak October close steps a holder down to 1%, and a daily close under 215 halves the position. New money gets 0.75% at most, only on a verified retest. The aggressive part isn't the size. It's refusing to let fear sell the floor at market, and being ready to pay up for information once the print arrives.

Conservative Analyst¶

Conservative Analyst: I'll start with what I agree on, because it narrows the disagreement. The business is getting better, the 1.25% first tranche for new money is affordable, the insider selling is mostly routine, and the retail posts are noise. My problem is with how the plan treats people who already own the stock.

Hold isn't the neutral choice you describe. Holding means choosing to own COHR at 237 at your current size, with everything that implies. The 29.8% drop in 11 sessions is already in the price, so it's not a reason to stay. If you wouldn't buy this size today, with the cash-flow question open and three binary events ahead, you shouldn't carry it. "Still up 96% on a year" is also an arbitrary anchor. From the 426.89 closing high, the stock has given back about 62% of its entire run from 120.79, and the weekly and daily trend tools are both down.

Your confirmation trigger confirms nothing. The October month-end close at or above 228.68 is a level that's $8.69 below today's price, while the daily ATR is $20.95. The stock typically moves more than twice that distance in a single session, and there are about seven sessions left, including the FOMC outcome the day before the month-end close. Whether it closes above or below 228.68 is close to a coin flip on noise alone. So the plan's cut trigger is a coin flip, and its first-tranche trigger is nearly already met. As for the "retest that holds on expanding volume," today's volume bar is incomplete, so that can't be verified, and the retest would be a fourth test of a floor in a stock making lower highs (440, 439.68, 391, 342). The bounce signals are real but thin. The TD-9 is complete and the MACD histogram narrowed once, but RSI has no divergence, the z-scores are nowhere near minus 2, and OBV confirms the selling.

Your risk-reward math uses the wrong starting point. You computed 1.7 to 2.4 times from a 228.68 entry, but nobody can transact there today. From 237.37, the stop at 215 is 9.4% away and the first target at 252-262 is only 6 to 10% away. That's roughly 0.65 to 1.1 times your risk, not 1.7 to 2.4. The stop is also not the structural, non-one-ATR stop you describe. One ATR below the close is about 216.4, so 215 is the one-ATR line, and yesterday's intraday low of 217.83 came within 1.3% of it. Stops don't protect against gaps either. If it gaps toward 195, which is the two-ATR reference the plan itself cites, the loss from 228.68 is about 14.7% against a 10 to 15% gain at the first target, so the ratio drops to roughly 0.7 to 1.0. Below 215 there's little traded structure until the December to February range, with lows around 167 to 175, roughly 26 to 29% under today's price.

On the fundamentals, you gave me the cash conversion point and then explained it away. Operating cash flow fell from $634M to $80M while revenue grew 22.5%, so working capital consumed the cash, not just capex. Non-cash current assets nearly doubled, and a big part of the 2.43 current ratio is that same build you admit could be written down. Cash alone covers about 41 cents per dollar of current liabilities, and current liabilities jumped $741M in the June quarter with the composition unknown. Debt-to-equity looks fine because equity roughly doubled, and the report infers that came from a preferred conversion and an equity raise, not from debt coming down. So the balance sheet funded the buildout with new shares, and the stock is now 44% off its high. By my rough arithmetic, derived June-quarter operating cash flow of about $70M against capex of about $556M is a burn near $490M a quarter. That puts the $1.16B of cash at roughly two to three quarters of runway before more borrowing or issuance. That's an extrapolation from derived numbers, but it's the right question to ask.

I'd also push back on "the denominator is growing into the price." Derived quarterly net income was $226M in September 2025 and about $223M in June 2026, with EPS around $1.19 and $1.20, while revenue grew about 29% over those three quarters. The capex that doubled this year hasn't reached the depreciation line yet, which is my inference, not a reported figure. Susquehanna's $350 doesn't help either. It's an 18% cut, it was singled out while AMD and QCOM got raises, and targets follow price down.

On insiders, I agree most of it looks routine, but the data doesn't confirm a 10b5-1 plan. Seven sales totaling about $8.2M came between August 18 and September 11 at $268 to $324. There has been no open-market buying through a 44% drawdown, apart from the CEO's roughly $103K in late 2024. Bain sold 7.5M shares at $143 last year and still holds about 7.75M. Whether it sells into the 252-262 rally you're counting on, I can't say.

On macro, you're treating recession odds of 8% as the relevant number. COHR's risk isn't a recession, it's AI-capex digestion, and that tail is rising, at 9% and up 3.1 points on the week. The Fed is priced for no cuts in 2026 at 97%, with a 12% chance of a hike next week, against a beta of 2.11 and 57.6x GAAP earnings. The sequence matters too. The FOMC resolves October 29, the month-end close that decides the plan is October 30, hyperscaler earnings fall in the same week, COHR's own print comes in early to mid November (the date isn't confirmed anywhere), and Nvidia reports around November 18. The plan holds full exposure through all of that.

The plan is also inconsistent with its own sizing rule. It sizes so a 20% gap costs 0.25% of the portfolio, which implies a position of about 1.25%. New money is capped at that, but existing holders can keep any size through the print. And 20% isn't a conservative gap for a stock that just fell 30% in 11 sessions with no earnings event.

I'd adjust the plan in three ways:

Existing holders: Trim to about 1.25% before the catalysts instead of waiting for a coin-flip month-end close, using today's bounce or the 252-262 gap. Size is the only real protection against an earnings gap.
New money: Stay out until the 10-K working-capital check is done, since that filing already exists and can be read today, and until the print shows operating cash flow recovering. Replace 228.68 with something meaningful, like the daily SuperTrend at 292.15.
Stop: Treat 215 as a trigger to review, not as protection.

Neutral analyst, if you're going to say wait and balance the two sides, waiting at full size is still an active bet through the highest-event-density stretch of the year. Conservative Analyst: I think we've converged more than the tone suggests, so let me say where, and then where I think you're both still off.

Aggressive, you've dropped the 228.68 buy trigger, the 96% anchor, the "over 4x" reward, and "earnings compounding," and you've accepted a halving on a daily close below 215 and a sell-half backstop on October 28. Neutral, you caught a real inconsistency in my plan: I can't tell new money to hold zero while telling existing holders 1.25% is fine through the print. I also agree 292.15 is a bad place to buy, since it's the bottom of the resistance cluster. I'll fix both. And I'll drop the market sale. Limit orders in the 252-262 gap are fine, since that's only 0.7 ATR away while 215 is 1.07 ATR down.

I won't move on size, and I have to hold myself to my own words. I said 20% isn't a conservative gap for a stock that fell 30% in eleven sessions with no earnings event, and then I kept the 1.25% that was built on 20%. Aggressive, you now say 30% is the gap you'd stress against. The trader's rule was a gap costing at most 0.25% of the book. Divide that by 30% and you get about 0.8%. Divide by Neutral's 25% and you get 1%. You raised the stress gap by half and then raised the loss budget from 0.25% to 0.6% by moving the cap to 2%. That means picking the size first and the gap second. So my number through the print is about 1% for COHR, and I'm not objecting to the word Hold, only to Hold meaning "whatever you own." Above 1%, ladder the excess into the gap. Below it, holding is defensible.

Aggressive told Neutral to pick one number and look at the basket separately. I think that's backwards. This drop came with "AI investment worries" headlines and AAOI down about 50% in six months. If someone also owns LITE, AAOI, GLW or MRVL, the thing that gaps is the AI-capex narrative, and it takes them all together. So the basket should govern, and we don't know this book, so that's the first thing the holder should check.

On lower highs, you say a failure at 288-295 still pays 21 to 24% against 9.4% of risk. That ratio holds if the stop fills at 215, and the stop has to work through the print. If the stock gaps to the two-ATR reference near 195, the loss is about 18%, and the ratio is closer to 1.2 to 1.4. The two earlier bounces were large, but you called them two episodes yourself, and a floor doesn't protect against a gap.

On the month-end trigger, October 30 is a Friday, so the first chance to act is Monday the 2^nd. Last year's gap day was November 6, so the print could be days later. You'd be cutting just before the event, alongside everyone else watching the same SuperTrend, on a signal you admit is close to a coin flip. That's why I prefer Neutral's October 28 date, which comes before the Fed decision.

On cash flow, you call it a recovery, from about minus $94M in March to about plus $70M in June. FY26 operating cash flow was $80M, so the first two quarters together made about $104M. A year ago it was $634M, about $158M a quarter. So the "recovered" quarter is under half of last year's quarterly average, on revenue about 34% higher, against roughly $556M of capex. Gross profit also rose about $208M from September to June while net income didn't move. You retired "earnings compounding," which I appreciate, but that was the valuation defense. Without it you hold 57.6x GAAP earnings, with a 17x forward multiple that probably rests on adjusted EPS. My own inference is that the $1.1B of capex hasn't hit the depreciation line yet. On dilution, "market access at $46.7B" describes today. Financing windows are procyclical, and the tail rising on the prediction markets is AI-capex digestion, which is what would close the window.

On insiders, a quiet week proves little. Trading windows typically close around quarter-end until after earnings. On Bain, one session of volume isn't how a 7.75M-share stake gets sold. It goes as a block, and the last one, 7.5M at $143.37, came on November 7, the day after the post-earnings gap. If that's the pattern, their window reopens just when the plan wants to sell into strength. I can't know that, but the discount on a $1.8B block matters more than daily volume.

On macro, 86% priced for a hold means a hold is no good news. The live Fed risk is the 12% hike, and a week ago hike odds were closer to a third, so I'd call the risk unstable rather than receding. You also can't discount the 9% bubble figure for thin volume and still cite the 8% recession figure, which has about the same volume. On "positioning can unwind," the data doesn't show a flush yet. RSI is 35 and never touched 30, the z-scores are minus 1.4 and minus 1.6, OBV shows no divergence, and the retail tape is buying Feb $300 calls with no labeled bearish posts. A stall on fading volume is what bulls hope for, but it isn't capitulation.

Neutral, on the 14% gap last November, that launched from about $135, and the stock is now about 76% higher. The forward EPS in the data is 3.4 times trailing, probably on an adjusted basis. A good print at $135 and a good print at $237 aren't the same setup, and one observation would cut either way.

For new money, I'll take your structure with my sizing. Do the free 10-K check today. If it passes, take 0.6% on a verified retest of 215-222 on expanding up-day volume. That's about what the 0.25% budget supports before a binary event, and Aggressive's 1.25% is twice that. Then add after the print on information, not price: inventory and receivables growing slower than revenue, a sensible capex guide, and operating cash flow moving the right way. Even at 292 the stock would be about 32% below its June closing high, so paying up to resolve the biggest unknown isn't buying the top. I'm fine with that cost.

So Hold works at about 1% or less, counted with the other AI optics names. Above that, ladder the excess into 252-262 and sell half of it at the October 28 close if unfilled. Cut the rest if October closes under 228.68, and treat a daily close under 215 as a halving trigger, not protection. We all agree the cash-flow question is the crux and none of us can resolve it from here. The one thing we control is how much a bad answer costs. Conservative Analyst: Let me start with where we agree, because it's a lot. Limit orders in the 252-262 gap, a decision by the October 28 close, a basket cap, a halving on a bad close, and a 0.75% starter for new money after the 10-K check all work for me. What's left is size, the "coin flip" assumption, and what the defaults should be when nobody knows the answer yet.

Aggressive, you say a 30% gap is a tail twice as big as anything observed, and that sizing for it leaves you underexposed everywhere else. But this stock just printed that tail. It fell 29.8% in 11 sessions with no earnings event. The only difference is that it came over eleven days instead of one, which means you could at least have sold. In a gap you can't. The 14% November gap is one observation, from $135, on a company a fraction of today's size. Also look at what the extra half point buys. Going from 1% to 1.5% adds about 0.075% to the book if the good case is a 15% move, and costs about 0.15% on a 30% gap. That is twice the loss for the same half point, on a book that probably already holds correlated names. So my position is this. Hold 1% until someone has actually read the 10-K, and if it comes back clean, go to the trader's own 1.25%, not 1.5%. The ceiling can rise in an afternoon once the filing is read, but a gap can't be undone.

On your breakeven math, I agree that a ratio of 1.2 needs only a 45% win rate. But the bad branch isn't only the 195 gap. Below 215 the next real structure is 167 to 175, which is 26 to 29% down. The good branch doesn't get all the way to 288-295, as you admitted. Dilution also belongs to the bad branch. A $2B raise is 4% on paper, but it arrives alongside a weak print and a lower stock, and the market usually punishes that more than the arithmetic. I'd also push on "coin flip." We all use it for convenience, and nobody has shown it's true. The crux is cash conversion, and with revenue up 13% sequentially and capex doubling, a clean operating cash flow number next quarter would be a surprise. I'd put the odds of an unambiguous cash answer below even. I can't prove that, but I don't see why the odds should be symmetric.

On the close-based stop, that's a fair distinction from a one-ATR stop. But the three closes that held were 219.65, 222.05 and 231.80, so on a closing basis the floor is closer to 220 than 215. A close-based line also does nothing in a gap, and the gap is the event we're sizing for. And a 215 close means selling the next morning at whatever the open is, in a stock that routinely ranges 5 to 10%.

On the other points, you say this isn't a rates story because the hike contract fell 20 points while the stock fell 30%. I agree, and that is the problem. A 30% drop that macro doesn't explain isn't fixed by a Fed hold. The things that resolve it are hyperscaler capex commentary and COHR's own print, and both are still ahead. The stall of three tight closes on fading volume is real, but a pause before a leg down looks the same, and today's bounce is on a bar the data itself flags as incomplete. That bar also opened at 240.44 and is trading at 237.37, so it's fading from its open, though I wouldn't lean on a provisional bar either way. And "the bar has been reset" cuts both ways. At 237 the stock is still 57.6x GAAP earnings and about 34x EV/EBITDA, nearly double where it was a year ago. It's cheaper than it was, not cheap.

Neutral, your 10-K consequence rule is the best idea on the table, and I'd add two items to it. Check whether there's a shelf registration or at-the-market program, because that tells you whether the raise is already prepared. Also see what the $741M jump in current liabilities is. If it's equipment payables, fine. If it's short-term debt, the ceiling drops. I also want the 3% basket cap to come with its price tag. If the basket gaps together, as the AAOI weakness suggests it can, 3% at a 30% move costs about 0.9%, which is nearly four times the trader's original budget. Whoever holds other optics names should see that number, not just the cap. And on your point that weak operating cash flow can't tell healthy from unhealthy, I agree. But then it can't support the bull case either, and the only cash evidence we have is weak.

For holders inside the ceiling, Aggressive wants an October close under 228.68 to be a review, not a sale. I'll accept that if the review has a default. If nothing changes, the default is the lower number, so it can't turn into holding out of inertia.

On new money, you asked me to pick between "292 is a bad place to buy" and "I'm fine paying it after a clean print." These are different purchases. Buying at 292 on a technical trigger with the print still ahead means paying 23% more for the same unknown. Buying there after a clean print means paying for the answer, and I'll pay that. The 0.75% starter on a retest is fine with me, as long as it's confirmed on a closed bar, since today's volume can't show anything yet. That also means you'll probably buy after the bounce, not at 215, so size it for the stop to be tested.

So my position is this. COHR at 1% until the 10-K is read, and 1.25% if it's clean. Count the other optics names in the basket and know what a correlated gap costs. Put limit orders in the gap now, decide on the excess by the October 28 close, and halve on a bad close. New money starts small after the filing check and adds only on information from the print. None of that gives up the upside. It just keeps a bad answer from costing much more than a good one pays. Conservative Analyst: I can sign most of this plan now, so let me say what I'm accepting and then name what's left.

The 27^th close is the right deadline for anyone over the ceiling. My memory of the Fed's calendar matches Neutral's, with the statement on the 28^th, but that's memory and not a tool result, so verify it. A weak October close stepping a holder down to 1% the following Monday works as a default. I also accept limits in the gap today, a halving on a close under 215, 0.75% for new money on a closed-bar retest after the filing, and sizing the optics basket by what it would lose rather than by weight. Neutral is also right that when I argued 1% versus 1.5%, I paired a modest up case with a stress down case. I'll stop doing that.

Four disagreements remain.

First, can reading the 10-K raise the ceiling? Aggressive, you say a clean filing takes the worst cash story off the table, so the stress gap drops from 30% to 25%. But the filing for the year ended June 30 should have been public since late summer, and the stock fell 30% in eleven sessions with it sitting there. The market already had the June balance sheet. What it doesn't have is the September quarter: operating cash flow, the capex guide, whether a raise is coming. No filing answers those. A clean read means the old numbers carry no flag, not that the print is safer. So the filing can veto but it can't license. Here is a trade. I'll accept 1.25% before the read, which is the trader's own number, since 1.25% at a 20% gap is exactly their 0.25% budget. In return the filing can only lower the ceiling, to 1% if flagged, and can't raise it to 1.5%. Everything we've learned in this debate pushed the stress gap up: operating cash flow under half of last year's quarterly average, non-cash current assets up 91%, and a 30% fall with no earnings event. The only thing pushing it down is a document nobody here has read.

Second, the loss budget has ratcheted. It started at 0.25%. It became 0.375% at 1.25% and a 30% gap, then 0.45% for COHR alone at 1.5%, then about 0.75% once Neutral's basket is counted. Each step looks small, but together they triple the budget, and each was justified by the last speaker's number. If the book can't absorb 0.75% across the optics names, the weights come down. The holder should compute that before choosing any COHR number.

Third, the ladder protects less than it sounds like it does. It shrinks what rides into the print only in the branch where the rally comes. A limit sell does nothing if the stock drifts sideways or lower and the print arrives at full size. There are also only four sessions to the 27^th close, Thursday, Friday, Monday and Tuesday, for a 6 to 10% move in a stock with an 8.8% ATR. Whatever doesn't fill goes at market on the 27^th. I'm fine with that, but the ladder is the upside and the 27^th close is the protection.

The same goes for hyperscaler prints being information. Capex commentary lands after the close and the stock opens on it, so acting on it means trading at the post-gap price. Meta's print comes before the 27^th, and I'll give you that. The other dates aren't in our data.

Fourth, "a bad answer costs under half a percent" holds only for COHR alone at 1.5%, and only if the loss stops at 30%. By Neutral's own arithmetic the basket is closer to 0.75%. The stock just showed it can lose 30% by grinding, and a close-based halving executes the next morning, below the line. That figure is a central estimate for a bad outcome, not a cap.

On the print itself, Aggressive, you accepted that the upside you can underwrite is about 14% against 18% down, which needs a good result more than 56% of the time to break even. You also said you aren't claiming an edge. The trader's reason for not buying was variance without an edge, and that applies to every share held through the print. I accept holding some, because selling to zero is its own bet. But that argues for the smaller number.

Finally, "44% off its high" keeps returning as a reason not to sell. It describes the path, not the price. At 237 the stock is still about 57.6x GAAP earnings and roughly 34x EV/EBITDA, with 97% priced for no Fed cuts this year. The test is whether you'd buy this size today, and my answer is 1.25%.

So I'm at Hold at 1.25% or less, counted with the other optics names, with the filing as a veto only. Limits go in the gap today, the 27^th close is the deadline for any excess, a weak month-end steps down to 1%, and a close under 215 halves. New money starts at 0.75% after a clean filing and a verified retest, and the rest waits for the print. Conservative Analyst: We're close enough now that I'll say what I'm accepting, then spend my time on the places where the plan still has holes.

Aggressive, you're right that the COHR line never moved. It's been 1.25% from the start, and what changed was the label on what a gap costs: 0.25% at 20%, about 0.375% at 30%. Calling that a ratchet overstated it. The genuinely new number is the group cost, and Neutral's method is right. The holder picks the loss the book can take if the optics names gap together, derives the weights, and cuts the other names before COHR. I'll also take your 40% case, a fall to about 142 costing half a percent, as the honest description of a bad outcome. And your point that paying 270 to 290 for the answer beats leaning in blind at 237 is the argument I've made since my first turn. If that's the aggressive position, the case for adding before the print is gone.

I don't want one thing lost in the convergence. You said the case for selling is gone because my number is the trader's 1.25%. The case for selling to zero is gone. The case for selling the excess isn't. The trader's plan says keep current exposure and trims oversized positions only if the filing check fails or October closes under 228.68. What we've agreed is that anyone above the ceiling is down to it by the 27^th close, unconditionally. That's the real change to the trader's plan. Hold means hold up to 1.25%, and a holder at 3% isn't following it.

On the ladder, you said a fill is likelier than not and that you hadn't computed it, so I ran a rough version. Backing daily volatility out of the ATR gives about 5.5% a day, or about 11% over the four sessions to the 27^th close (Thursday, Friday, Monday, Tuesday). On a driftless walk, that's roughly a 55 to 60% chance of touching 252, about one in three for 262, and about a 35 to 40% chance of trading through 215 over the same stretch. It's crude, and the ATR is inflated by the selloff. Still, the first rung is close to a coin flip and the downside line is almost as reachable as the top of the gap. So the ladder is a bonus and the 27^th close is the plan.

Since 215 can break before the 27^th, the halving needs two details. It applies to whatever you hold at the time, and if that's still above the ceiling, the 27^th rule still applies. After a halving, nothing gets added back before the print. A starter bought on the retest should be sold outright on a close under 215, not halved. Its premise was that the floor holds, and halving a 0.75% position leaves a stub and another decision.

On upsizing after the print, you want 2% and Neutral wants a reason beyond the print. I can live with 2%, but only if "clean" is written down before the number lands, because after a gap-up everyone finds a reason. I'd require four things: - Inventory and receivables growing slower than revenue. - Operating cash flow positive and rising from the roughly $70M derived June quarter. - A capex guide with a funding plan that doesn't include a new raise. - The add made on a closed bar after the gap day, not into the gap.

If all four hold, the ceiling goes to 2%. Otherwise it stays at 1.25%. I'd stop at 2%, not 2.5%. At 2%, a 30% stress costs 0.6%, more than twice the trader's budget. A clean quarter doesn't settle Nvidia around the 18^th, the financing window, or the fact that at 270 to 290 you're still in the 60s on trailing GAAP earnings with a beta of 2.11. The trader's 2.5% should need a second clean quarter.

On dates, confirm the earnings date today, because a rule keyed to the last close before the print can't run off a date no tool returned. If it isn't confirmed by the 27^th, assume the first week of November, since last year's gap day was November 6, and treat the Monday after month-end as the last chance to step down. Verify the Fed day as well. The macro report has Meta in focus this week, so the first live capex read-through may land before any of these rules are tested. That means the limits should be in today and the 215 rule live from tomorrow's open.

On the starter, Aggressive, you're right that a retest rule that never triggers isn't a failure. A miss costs opportunity only, and a miss is the cheapest way to be wrong in this setup. I'd rather the plan be slow to buy than quick to buy into the densest event stretch of the year.

I also agree with Neutral that no edge argues against selling to zero as much as against buying. That's why I'm at 1.25% and not zero.

So my position is Hold at 1.25% or less, counted with the other optics names, and priced by what the group loses if it gaps together. The excess is gone by the 27^th close, with limits in the gap today. A close under 215 halves a holding and exits a starter. A weak October close steps down to 1%. A flagged filing caps the ceiling at 1% and blocks new money. A clean filing changes nothing for holders and permits a 0.75% starter on a closed-bar retest. After the print, a written checklist can lift the ceiling to 2%, no higher. None of this requires knowing what the September quarter says, which is the only honest property a plan can have right now.

Neutral Analyst¶

Neutral Analyst: You've each found real flaws in the plan, but I think you both over-correct, so let me go through where I land.

Aggressive first. Your best point is that the cash-flow question is the crux, the print resolves it, and the plan adds nothing until then. I agree with that. But the risk-reward math doesn't hold up. The 1.7 to 2.4 times figure runs off 228.68, and the stock closed at 237.37. There's also a subtler problem. The trigger is a close at or above 228.68, so the better the confirmation, the worse the math gets. If October closes at 245, your real entry is 245 against a 215 stop. That's about 12% of risk for a first target only 3 to 7% away. From today it's roughly 0.66 to 1.1 times to the gap, and about 2.3 to 2.6 times to the 288-295 cluster, not over 4.

I also wouldn't call 215 a structural stop. It sits under three dated lows, yes, but it's also one ATR below the close, and yesterday printed 217.83 intraday. With an ATR near 9%, noise tests that level, and a gap makes it moot. You also cite the bounces to 347 and 379, then admit it's two episodes, and then lean on them to justify carrying size through the print. Each of those rallies topped lower than the last (440, 439.68, 391, 342). And 8% recession odds and 9% bubble odds don't capture COHR's risk. The stock just fell 30% in eleven sessions with no earnings event and those odds barely moved.

Conservative, you're right that a coin-flip trigger isn't protection and that the risk-reward is worse than presented. But your plan fails its own test. If the test is "would you buy this size today," new money stays at zero while existing holders keep 1.25%, and that's inconsistent. Either 1.25% is an acceptable position through the print, in which case a modest starter for new money isn't absurd once the free 10-K check passes, or it isn't, and you should be selling to zero.

I also wouldn't trim at market today. The daily TD-9 is complete, the MACD histogram narrowed for the first time, and the price sits in the bottom 15% of the Bollinger range on a floor that has held three times. You'd be selling at the least attractive spot in weeks, when the 252-262 gap is only 6 to 10% higher.

On runway, you labeled it an extrapolation, which I appreciate, but I'd push on it. Cash fell about $430M from March to June, not $486M, so something else funded part of the burn. The company raised roughly $1.85B in the March quarter and has market access at a $46.7B cap. The $741M jump in current liabilities could be equipment payables, which cuts both ways. So I wouldn't call it a two-quarter runway. I'd call it a high probability of more financing. That's a dilution risk for the stock, not a solvency risk, so what to watch is the capex guide and any raise or convert.

Your 292.15 re-entry trigger is also the daily SuperTrend, 23% above the price and at the bottom of the confluence cluster you identified as resistance. Buying there means paying for the whole rally and entering where the 50- and 200-day averages sit. That's the "buy after the money is made" problem Aggressive raised, and on this point they're right.

Gating on operating cash flow recovering is also blunt. With revenue up a derived 13% sequentially, a healthy business can show weak cash flow from inventory build. I'd watch whether inventory and receivables grow slower than revenue, plus the capex guide, more than one quarter's OCF.

Both of you are also leaning on numbers that are softer than they look. Derived June-quarter net income of $223M against $226M in September is arithmetic, and there's a $17M mismatch between the two net income figures in the data, about 8% of a quarter. So neither "earnings compounding" nor "earnings flat" is safe to assert. What I can say is that derived revenue growth of about 34% and gross margin near 38.5% haven't clearly reached the bottom line yet.

So here's my version. I keep the Hold, but with a size band and dates attached.

First, count COHR together with your other AI-optics exposure. It trades with LITE, AAOI, GLW and MRVL, so 1.25% should be a bucket cap, not a COHR-only number.

Second, if COHR is at or under about 2% of the portfolio, hold through the print. A 25% gap on 2% costs half a percent, and the one large gap visible in the data, early November last year, was up about 14%. That's one observation and not an edge, but it shows the gap cuts both ways.

Third, if you're above 2%, trim the excess in stages. Put limit orders in the 252-262 gap. If they haven't filled by the October 28 close, sell half the excess at market. If October closes below 228.68, take the rest down. That moves the first decision ahead of the October 29 FOMC and the hyperscaler prints. The plan's month-end trigger comes after the events it's meant to protect against.

Fourth, treat a daily close below 215 as a pre-committed halving, not as protection. A gap toward 195 is about 18% from here, and the only real defense against that is the size you carry.

Fifth, for new money, do the 10-K check today. If it passes, take a starter of about 0.6%, and only on a 215-222 retest that holds on expanding up-day volume, which can't be verified today because the volume bar is incomplete. Don't buy on the 228.68 close. Build to the full tranche only after the print shows inventory and receivables behaving and capex guidance is sensible.

This keeps you exposed to the gap fill and to a rebuild after the print, and it caps the damage if the cash-flow worry turns out to be right at a fraction of a percent of the portfolio. Neither of you gets exactly what you wanted, which is probably the right sign. Neutral Analyst: We've narrowed this to a few real disagreements, so let me name them and say where I land, starting with where I have to correct myself.

Aggressive is right that I called 1.25% a bucket cap and then said to hold anything under 2% for COHR alone. Those don't fit together. Conservative is right that last November's 14% gap launched from about 135, so it says little about a print at 237 after a 30% drop. I'll keep the narrow point that gaps cut both ways, but I won't use it to justify size.

On size, you're both picking a number first and backing into a stress gap. The trader's 0.25% loss budget was built on a 20% gap, and we all agree 20% is too gentle for this tape. But 0.25% isn't sacred either. A 30% stress gap and a budget of 0.25% to 0.5% of the book gives a range of roughly 0.8% to 1.7%. I'd put the hold-through-the-print ceiling at about 1.5% for COHR, which costs 0.45% on a 30% gap. That's above Conservative's 1% and below Aggressive's 2%. It's the upper half of a defensible budget, not a midpoint for its own sake.

Conservative is right in principle that the basket matters, because the AI-capex narrative gaps these names together and AAOI down about 50% is evidence of that. But "the basket governs, so COHR gets 1%" leaves a holder without a usable rule. So use two numbers: COHR at most 1.5%, and COHR plus LITE, AAOI, GLW, MRVL and similar at about 3% combined. If you already hold 2% in other optics, COHR's room is about 1%.

For new money, you each set the starter at roughly 60% of your holder number, which is fine. I'd use half the ceiling, about 0.75%, only after the 10-K check and only on a verified retest of 215-222. Aggressive, 0.6% is too small to matter, but a starter that matters is the one that hurts in a gap, and you've conceded you have no edge on the print. Conservative, your own rule doesn't give 0.6%. At a 30% gap, a 0.25% budget supports about 0.8%, so 0.75% is consistent with it. The second half waits for the print, because that's the only thing that answers the cash-conversion question.

Aggressive, the 21-24% payoff to the 288-295 cluster isn't independent of the print. Getting there within three weeks means surviving the print, which you've said is a coin flip. The pre-print payoff you can actually underwrite is the 252-262 gap fill, 6 to 10% against a stop 9.4% away. That's a hold you manage for variance, not one you lean into. On the Fed, hike odds falling from about a third to 12% is good news, but 97% for no cuts in 2026 is the regime the stock fell 44% inside. That isn't a tailwind arriving.

Conservative, you're right that the recovered quarter's roughly $70M of operating cash flow is under half of last year's quarterly average on 34% more revenue. But a company growing 13% sequentially with capex doubling would show weak operating cash flow from inventory and receivables whether the business is healthy or not. The number doesn't discriminate between those cases. The composition does, which is why the 10-K comes first. Also, you and Aggressive each lean on thin Polymarket contracts when it suits. The 9% bubble and 8% recession figures both sit in $2-3M markets, so drop both. The evidence of AI-capex digestion fear is then the price action itself, which I agree deserves respect and is another reason for the ceiling. On Bain, one block the day after a gap is a pattern of one. I'd read it as a reason to ladder sells before the print, nothing stronger.

Your "no flush yet" point is right, and it supports my side. RSI hasn't touched 30, the z-scores are about -1.4 and -1.6, and OBV shows no divergence. So the bounce isn't guaranteed, and you shouldn't buy size into it. But there's also no capitulation to sell into, so you shouldn't dump at market. That's the case for limit orders.

On mechanics, today you should check the 10-K and confirm COHR's earnings date, since no tool returned it. Put limit orders in the 252-262 gap now. The sell-half decision should come at the close before the Fed statement. The report has the meeting on the 28^th and 29^th, so verify the day, because if the statement lands on the 28^th, that close already includes it. Meta's print is in focus this week, so some capex read-through arrives before then. Conservative is right that October 30 is a Friday, so the month-end close confirms a decision already made. If October closes under 228.68, anyone still above the ceiling finishes cutting on Monday. A daily close under 215 means a halving for everyone.

The 10-K check should have a consequence. Say inventory growth is mostly raw materials and work in process, receivables aren't stretching, and the $741M jump in current liabilities is equipment payables. That supports the 1.5% ceiling and the second half of a starter. If finished goods are piling up, receivables are stretching, or debt is coming due, cut the ceiling to 1% and skip new money until the print. I'd settle that before touching size, because it's free and it's the one part of the cash-flow question we can answer today.

So my answer is still Hold, but with numbers: about 1.5% for COHR, about 3% for the optics basket, limits in the gap, a decision before the Fed and hyperscaler prints, a halving under 215, and a split starter for new money. Aggressive keeps a seat at a floor that has held three times. Conservative gets a position where a 30% gap costs under half a percent. Nobody has shown the print is anything but a coin flip, and a plan that survives either outcome is the only kind worth carrying through one. Neutral Analyst: We're now arguing over a quarter point of portfolio. The gap between Conservative's 1.25% and Aggressive's 1.5% is about 0.075% of the book on a 30% gap, which is smaller than the error in any of our inputs. So I'll spend this turn on what decides the outcome, and on where each of you is still bending the math.

Aggressive, your breakeven argument is neat but mismatched. You pair the 288-295 cluster, 21 to 24% up, with a gap to 195, 18% down, and say a coin flip clears it. The only upside gap anyone has observed is 14%, which is about 270 from here, and the cluster needs follow-through on top of that. Pair 14% up with 18% down and breakeven is about 56%. Pair it with your own 30% stress and it's about two-thirds. The print isn't a free option even if it is a coin flip, and nobody has shown that it is one. The close-based stop is a fair distinction, but a close under 215 means selling the next morning in a stock that routinely ranges 5 to 10%. The realistic fill is below the line. That's why halving beats exiting, and why size matters more than the level.

Conservative, you make the mirror-image mistake. Going from 1% to 1.5% adds 0.075% on a 15% good case and costs 0.15% on a 30% gap, and you call that twice the loss. But you used a modest number for the up branch and a stress number for the down branch, which is what Aggressive did in reverse. The comparison needs probabilities, and you've admitted you can't prove yours. I'd also separate your claim about "a clean cash answer" from the odds of a good price reaction. With revenue up 13% sequentially, weak operating cash flow is the expected result whether the business is healthy or stuffing a warehouse. The stock doesn't need a clean answer, only a composition that isn't worse than feared. Aggressive is right that the 30% drop reset the bar for the price reaction. You're right that it didn't reset the cash-conversion question. Both can be true.

On the basket, I agree the holder should see the price tag, but a flat 30% across the group overstates it. Corning is a much steadier name than COHR, and AAOI's collapse doesn't mean MRVL gaps with it. So I'd define the basket by loss instead of weight. COHR at 1.5% under a 30% stress costs about 0.45%. The other optics names at something like 20% each add maybe another 0.3%, so roughly three-quarters of a percent for the whole group. If the book can't absorb that, the weight cap comes down. That makes the 3% a derived number instead of a guess. On your 10-K additions, a shelf registration is usually boilerplate for a company this size. I'd look for an active at-the-market program, language tying the capex plan to outside funding, and what the $741M jump in current liabilities actually is.

Here is my compromise on size. Until someone has read the filing, the ceiling is the trader's own 1.25%. If the filing is clean, it goes to 1.5%. If it's flagged, with finished goods piling up, receivables stretching or current debt, it drops to 1%. That respects Conservative's point that you shouldn't set size blind, and Aggressive's point that the ceiling shouldn't stay low out of inertia. It costs an afternoon.

On the month-end line, I side with Conservative on the default and Aggressive on the size of the step. A dollar under 228.68 carries the same information as a dollar over, so it shouldn't trigger an exit. But for holders inside the ceiling, the default on the following Monday should be a step down to 1% unless the filing and the hyperscaler commentary gave you a reason to stay. The line should never be a buy trigger. We all now agree that the stronger the confirmation, the worse the entry.

Two dates need checking before anything else. First, the Fed. The contract resolves October 29 and the report says the meeting runs October 28 to 29. My own recollection of the 2026 calendar, which isn't from these tools, is that the meeting ends on the 28^th. If so, the statement lands at 2pm that day and the 28^th close already includes it, which defeats the purpose of deciding before the Fed. In that case the deadline is the 27^th. Second, the earnings date. Last year's gap was November 6. If this year's print comes earlier, the month-end rule acts too late.

For new money, I'll stay at 0.75% on a closed-bar retest of 215-222, after a clean filing. The original 1.7 to 2.4 reward-to-risk was a fair price for a 228 entry, and the flaw was the trigger. You only get that ratio by buying near 228 or lower, so the retest is the one trigger that delivers it, and buying at 237 doesn't. The second half comes after the print, if inventory and receivables grow slower than revenue and the capex guide makes sense.

So my answer is still Hold, as a set of conditions. Start with a 1.25% ceiling for COHR, moving to 1.5% or 1% once the filing is read, and size the basket by loss. Put limit orders in the 252-262 gap now, and cut any excess by the pre-Fed close. Step down to 1% on a weak month-end, halve on a daily close under 215, and start new money at 0.75% on a retest. Aggressive keeps a seat at a floor that has held three times. Conservative gets a position where a 30% gap costs under half a percent. None of the three outcomes, good cash, bad cash or no clear answer, forces you to sell at the worst price. Neutral Analyst: We're now arguing about quarter-points, so I'll move quickly on what doesn't matter and spend time on what does.

Conservative, you've persuaded me on the 10-K, and I'm dropping my proposal that a clean read lifts the ceiling to 1.5%. Your point that the market already had the filing is borne out by our own data. Insiders were selling at 268 to 324 in late August and early September, and the stock was still 337 on October 2. The document sat in public for six weeks and the stock then fell 30%. So the filing can't explain the drop, and it can't tell us what the September quarter looks like. It can show a flag in the June balance sheet, which is a reason to cut, not to add. So 1.25% is the ceiling going into the print, a flagged filing drops it to 1%, and only the print lifts it. Aggressive, that costs you a quarter-point. But you wanted the stress gap lowered because we'd "learned something," and reading old news isn't learning something. The way to earn 1.5% is to get through the print.

I won't go as far as saying everything pushed the stress gap up, though. The 30% fall is partly the bad news already being paid for, and a stock that has already lost this much doesn't necessarily have a bigger gap left. We can't measure that, which is why we size to the stress case and don't argue about it.

On the ratchet, you're right about the order of operations and a bit off on the arithmetic. COHR alone has gone from 0.25% to 0.375%, and that's fully explained by moving the stress gap from 20% to 30%, which all three of us accepted. The 0.75% is a different object, the whole optics group. But we have been picking weights and then computing losses, and it should run the other way. The holder picks the loss they can live with if the group gaps together, then derives weights. My default is about 0.4% for COHR at a 30% gap, which is the 1.25%, and about 0.75% for the group. If the book can't take that, the other optics names come down before COHR does.

Your ladder point is fair, but there's something to add. With an ATR near $21, the 252 gap is only about $15 above the close, less than a typical day's range. The volatility that makes a tight stop unreliable also makes a resting limit order fill more readily than it sounds. That's still not certain, and it only helps in the rally branch. So I agree: the ladder is the upside and the 27^th close is the protection. I'd also say that "no edge, so go smaller" applies to selling too. Selling to zero is a bet on a bad answer. A 1.25% cap is how you stop being the bet in either direction, so I don't need a second reason to go lower. I do need the holder to know the dollar figure. And I'd correct my own earlier phrasing: "a 30% gap costs under half a percent" is a central estimate, not a cap. A grind plus a next-morning halving can cost more.

Aggressive, three things. First, "the cheapest exit is a limit order 6 to 10% higher" is true in the branch where it fills. If the stock sits at 235 for four sessions, you're selling at market on the 27^th. That's fine, but say it. Second, "44% off its high" is the same kind of anchor as the 96% you already dropped. At 237 it's still 57.6x GAAP and about 34x EV/EBITDA. Third, hyperscaler results are information, but Microsoft, Alphabet and Amazon generally report in the last week of October (my recollection, not tool data), and they report after the close. Most of that lands after the 27^th close and arrives as an opening gap. A holder at the ceiling still carries it, which is another reason the ceiling shouldn't be higher.

For new money, I'm at 0.75%, counted inside the ceiling, on a closed-bar retest after the filing check. A retest of 215-222 sits below 228.68 by construction, so you'd be buying while the regime signal is failing. That's one more reason the starter stays small. The stop is cheap because it's only a few percent below entry. The real risk is a gap while you hold, so decide in advance whether the starter rides the print. If it fills at the 252-262 gap, I'd let it do its job and sell it. After the print, the total can rise as information arrives. The trader's 2.5% only makes sense after a clean print, and even then I'd treat 2% as where you need a reason beyond the print itself.

Two dates need checking. My recollection is that the FOMC meets October 27-28 and the statement lands on the 28^th, though the report says 28-29. The 27^th close sits before the statement either way, but verify it. And COHR's earnings date still hasn't been confirmed. If it comes earlier than last year's early-November pattern, the whole timeline compresses.

My answer is still Hold. The ceiling is 1.25% going in, 1% if the filing is flagged, and only the print can raise it. Limits go in the 252-262 gap today, any excess is gone by the 27^th close, and a weak October close steps a holder down to 1% the following Monday. A daily close under 215 halves the position, the optics basket is sized by what it would lose, and new money starts at 0.75% only after a clean filing and a verified retest. Aggressive keeps a seat at a floor that has held three times. Conservative gets a position where a bad answer is survivable. Neither of you has shown the print is anything other than unknowable, and a plan that doesn't need that answer is the one worth carrying through it. Neutral Analyst: We've converged on most of it, so I'll stress-test the pieces we all just signed off on, because a few are weaker than they sound.

Start with the ladder. Conservative's math looks right to me: about 5.5% a day backed out of the ATR, about 11% over the four sessions to the 27^th, roughly 55 to 60% odds of touching 252, a third for 262, and a bit over a third for 215. But follow it through. On that same driftless walk, a limit ladder with a market backstop on the 27^th has the same expected sale price as selling today. It doesn't make you money. It changes when you find out. So Aggressive's "a limit beats a market order" only holds if the bounce signals carry edge, and they carry little: a complete daily TD-9, one narrowing MACD bar, weekly TD at 2, z-scores nowhere near -2, and a provisional bar today. Conservative's "trim now" isn't a free lunch either. The choice is about variance. For someone slightly over 1.25%, four sessions of exposure on the excess is a rounding error, so ladder it. For someone at 3% or more, I'd now sell a third of the excess into today's bounce and ladder the rest. I said earlier I wouldn't trim at market, and I'd soften that, because my "least attractive spot" argument leaned on the same thin signals.

Second, the 215 rule. We keep saying a close-based halving gets executed the next morning, below the line. It doesn't have to be. If the stock is under 215 in the last minutes, you can act in the closing auction. That fixes ordinary days. It doesn't fix the print, which comes after the close, so the gap is the information. Write the rule for that day too: if the stock opens under 215 after the print, that day's close is the decision, and you act that afternoon. Aggressive, there's also a hole in your post-print plan. If the stock gaps to 280 and you add toward 2%, a stop at 215 is 23% away and means nothing. The stop has to move to the gap-day low or the 228.68 regime line, and you write that down at the same time as the add.

Third, Conservative's checklist. I like writing "clean" down before the number lands, but two items are traps and one is too soft. A funding plan with no new raise fails in exactly the good scenario, because companies often issue equity or converts right after a strong print, when the window is open. A raise priced into strength isn't a rescue raise, so judge the size, the price and whether it was already in the guide. Inventory and receivables growing slower than revenue is a high bar in a quarter where revenue is up around 13% sequentially and capex is doubling, so grade it. I'd want composition to be raw materials and work in process, not finished goods, and receivable days not stretching. The cash bar of "positive and rising from $70M" is the opposite problem, since dollars rise mechanically with scale. Conversion is the better test. The derived June quarter was about $70M on $223M of net income, roughly 30%, against 10% for the year. Beat that, not just the dollar figure. And make the lift graded. A full pass takes the ceiling to 2%, a partial pass to 1.5%, and a fail leaves it at 1.25% or lower. All-or-nothing means a good print never moves you.

On the stress budget, the 0.25% was built against an earnings gap. After the print, that gap is gone, though not the Nvidia report around the 18^th or the financing window. So 2% after a pass isn't a break from the trader's logic, but it isn't free either. At a 25% stress it costs 0.5%.

Neither of you has shown the print is more than a coin flip, so none of this depends on being right about it.

Here is where I land. The ceiling for COHR is 1.25% going in. A flagged filing drops it to 1% and blocks new money, and only the print can raise it. I don't know your book, so the check is yours to run. 1.25% costs about 0.4% in a 30% gap, and the other optics names add roughly another 0.3% if they fall together. If your book can't absorb about 0.75% across the group, shrink the other names first, then COHR. Limits go in the 252-262 gap today. Anyone slightly over is down to the ceiling by the 27^th close, and anyone far over sells a slice now. A weak October close steps you to 1%. A close under 215 halves a holding and exits a starter, with the gap-day exception above. New money is 0.75% inside the ceiling, only after a clean filing and a closed-bar hold of 215-222. If that retest never comes, you've lost nothing. Verify the FOMC day and the earnings date today, since no tool returned either.

My answer is still Hold. Hold means holding up to the ceiling, not whatever you happen to own.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Hold

Executive Summary: Hold COHR, but cap the position at about 1.25% of the portfolio through the September-quarter print. If you hold more than that, place limit sells in the 252-262 gap now and sell any unfilled excess by the Oct 27 close; if you are at 3% or more, sell a third of the excess into the current bounce first. Pre-commit three rules: an October close below 228.68 steps you down to 1%, a daily close below 215 halves a holding (or exits a starter), and nothing is added back before the print. New money waits for a clean FY26 10-K read and a closed-bar hold of 215-222 on expanding up-day volume, and even then buys only 0.75%; the 1-2 month objective is 259, with gap risk toward 195.

Investment Thesis: Why Hold and not Overweight. The debate settled direction as a genuine coin flip into the print, and no analyst showed an edge.

Cash conversion is the open question. FY26 operating cash flow was $80M against $787M of net income and $1.10B of capex, leaving FCF of about -$1.02B. The derived June quarter was about $70M of OCF against about $556M of capex. Several items remain unexplained: - A $741M jump in current liabilities. - Non-cash current assets up 91%. - Derived quarterly net income flat at $226M (Sep-25) vs about $223M (Jun-26), despite roughly 29% revenue growth. - A $787M vs $770M mismatch in net income.

Valuation is still 57.6x TTM GAAP earnings and about 34x EV/EBITDA, with a beta of 2.11. The primary trend is down: - Weekly SuperTrend is down with its stop at 395.74. - Daily SuperTrend is down at 292.15. - The 50-SMA (293.22) sits below the 200-SMA (295.19). - ADX is 35.56, and OBV confirms the selloff.

The aggressive analyst conceded that from 237.37 the 215 stop is 9.4% away while the gap target is only 6-10% above, about 0.66-1.1x reward to risk. They also accepted the neutral analyst's correction: pairing the observed ~14% upside gap with an ~18% gap to 195 needs a win rate of roughly 56% just to break even.

Why not Underweight or Sell. The business is accelerating: - Revenue went $4.71B, $5.81B, $7.12B. - Gross margin rose from 30.9% to 37.5%, about 38.5% in the derived Q4. - Reported YoY growth went 17.3%, 17.5%, 20.6%. - Solvency is sound: current ratio 2.43, D/E 0.32x, net debt about 1.6x EBITDA.

The price sits on a 215-222 floor that has held on a closing basis three times (219.65, 222.05, 231.80). The daily TD-9 is complete, the MACD histogram narrowed from -9.85 to -8.96, and the monthly SuperTrend is still up at 228.68. Selling to zero is itself a bet on a bad print.

How I weighed the analysts: - Conservative won on sizing. A 0.25% loss budget at a 30% stress gap supports about 0.8%, and 1.25% at 30% costs about 0.375%. Conservative also won on treating the 10-K as a veto only: it was public for six weeks before the 30% drop, so it cannot license a bigger position. And excess above the ceiling must go unconditionally, which is the real change from the trader's plan. - Neutral won on several points. The ladder is a variance choice, not free money, because under a driftless walk it has the same expected value as selling today. The optics basket (LITE, AAOI, GLW, MRVL) should be sized by loss: about 0.75% combined, cutting other names before COHR. The post-print checklist should be graded. And the deadline should fall before the FOMC statement, which is why I use the Oct 27 close. - Aggressive won on not dumping at market into a stall on fading volume (9.95M down to 6.15M), and on 292 or 228.68 being bad buy triggers.

Post-print rules, written now: - A full pass lifts the ceiling to 2%, a partial pass to 1.5%, and a fail keeps it at 1.25% or lower. The 2.5% level needs a second clean quarter. - The pass criteria are: inventory build in raw materials and WIP rather than finished goods; DSO not stretching; OCF conversion above the derived June quarter's roughly 30% ($70M on $223M); and a funded capex guide, with any raise judged on its size and price. - Add only on a closed bar after the gap day, and move the stop to the gap-day low or 228.68.

What changes the call: - Toward Overweight: a clean filing plus a clean print. - Toward Underweight or Sell: a flagged filing (finished goods piling up, stretched receivables, or current debt inside the $741M), which also cuts the ceiling to 1% and blocks new money. The same applies to OCF below about $70M, or accrual capex at or above about $500M with sequential revenue growth below about 5%. - A daily close below 215 opens thin structure toward 170-210.

Price target derivation. A valuation objective is not usable: - Forward EPS of $13.92 x 17.1x is about $238, which only reproduces the current price, and the forward EPS is likely on an adjusted basis. - Susquehanna's $350 was a cut target, and its own proponent withdrew it.

I therefore use a technical objective: the 10-EMA at 259.04, inside the unfilled 252.28-261.90 gap. That gives 259, or +9.1% (259 / 237.37). As a cross-check, derived run-rate EPS of about $4.80 ($1.20 x 4) puts 259 at about 54x, inside the research manager's 57x valuation gate. The downside references are 215 (-9.4%) and 195 (-17.8%).

Data gaps: - The earnings date is unconfirmed (assume the first week of November; last year's gap came Nov 6). - The FOMC day needs verifying (Oct 28 or 29). - The Oct 21 bar is provisional (3.05M shares). - Q4 figures are derived, not reported. - There is no revolver, covenant or inventory/receivables split in the data.

Current Price: 237.37

Price Target: 259.0

Confidence: Medium

Time Horizon: 1-2 months